Transcriptional Targeting in Cancer Gene Therapy

Tracy Robson* and David G. Hirst

School of Biomedical Sciences, University of Ulster, Newtownabbey, Co. Antrim, BT37 0QB, Northern Ireland, UK

Received 10 June 2002; accepted 19 July 2002

Cancer gene therapy has been one of the most exciting areas of therapeutic research in the past decade. In this review, we discuss strategies to restrict transcription of transgenes to tumour cells. A range of promoters which are tissue-specific, tumour-specific, or inducible by exogenous agents are presented. Transcriptional targeting should prevent normal tissue toxicities associated with other cancer treatments, such as radiation and chemotherapy. In addition, the specificity of these strategies should provide improved targeting of metastatic tumours following systemic gene delivery. Rapid progress in the ability to specifically control transgenes will allow systemic gene delivery for cancer therapy to become a real possibility in the near future.

INTRODUCTION

Gene therapy is the transfer of exogenous genes, called transgenes, into the somatic cells of a patient to obtain a therapeutic effect. Initially, gene therapy was viewed as an approach for treating hereditary diseases, but its potential role in the treatment of acquired diseases such as cancer is now widely recognised. In theory, gene therapy offers the potential for enormous improvements in the targeting of cancer therapy, but it is clear that this has not yet been achieved, although early trials are promising.

One of the main goals for all cancer therapies is the selective targeting and killing of tumour cells, thereby increasing the therapeutic ratio. Both chemotherapy and radiotherapy induce dose limiting normal tissue toxicities, which reduce their clinical effectiveness. Cancer gene therapy has the advantage that normal tissue toxicity might be avoided if suitable strategies can be employed to target the therapeutic transgene directly to tumour cells; an outcome that conventional therapeutic approaches have failed to achieve.

To date, clinical trials have focused on the delivery of genes directly to the tumour site by intratumoural injection using both viral and nonviral delivery agents, thereby largely avoiding normal tissues. However, the goal of most cancer gene therapy is to be able to administer a suitably packaged transgene systemically and achieve a high level of tumour targeting. This will be important for targeting the majority of tumours, that are not accessible for direct injection, and to ensure adequate distribution of the transgene throughout the tumour mass. The blood supply still offers the best opportunity to do this. Systemic delivery of transgenes would also allow targeting of both the primary tumour and metastatic deposits, which must be controlled if therapy is to be successful. A number of strategies are now being developed to target both viral and nonviral delivery agents to tumour cells. These include exploitation of natural viral tropisms, such as those exhibited by adenoviruses to target lung epithelium; re-targeting viruses using a bispecific molecule to simultaneously block native receptor binding, redirecting virus to a tissue-specific receptor; genetically modifying the virus to ablate native receptor interactions and incorporating a novel ligand into one of the virus’ coat proteins; using tissue-specific ligands or monoclonal antibodies incorporated onto the surface of liposomes to direct them to target cells. A detailed description of these targeted delivery strategies, lies beyond the scope of this review (for reviews covering this area see references [1, 2, 3, 4]).

As well as controlling the delivery of the therapeutic gene to the tumour tissue, controlled regulation of transgene expression is now playing a major role in targeted cancer gene therapy strategies. Indeed, by combining targeted delivery with tumour-specific expression, the level of transgene product in nontarget normal tissues, compared with that in tumours, can be greatly reduced. The purpose of this review is to focus on transcriptional targeting of transgenes, which will undoubtedly be an essential component of systemic cancer gene therapy.

TRANSCRIPTIONAL CONTROL OF EXPRESSION

In the last decade, it has become increasingly clear that gene expression is regulated by a complex interplay of factors that function in a cell-type-specific manner to produce diverse effects. These subtleties arise from the balance of tissue-specific transcriptional control elements present in the various cell types, for example, hepatic, melanocyte, neuronal, and erythroid or tumour-specific promoters/enhancers that are activated...
in diseased states, or as a result of being exposed to an unfavourable tumour-associated microenvironment, for example, hypoxia. These cis-acting elements can be harnessed to drive the transcription of a therapeutic gene in a tissue- or tumour-specific manner (Figure 1). The use of tissue-specific cellular promoters to restrict transgene expression usually results in constitutive expression in the target tissue. However, for some therapeutic strategies, it will be preferable to regulate the duration and level of expression exogenously. This may be achieved by the use of cellular promoters that are preferentially activated under certain conditions to drive transgene expression in the target cell population. Research has focused on promoters induced by ionising radiation, heat, and small molecules. The use of tissue- and tumour-specific and exogenously controlled inducible promoters will now be discussed, as well as novel molecular adaptations of these promoters to strengthen gene expression. However, because the number of promoters that have been used for transcriptional targeting of transgenes for cancer gene therapy is very large, it is not feasible to discuss all of these in detail. The available data to date will therefore be presented in a series of tables.

TISSUE-SPECIFIC PROMOTERS

Transcriptional targeting utilising tissue-specific promoters exploits genes that are switched on only in certain tissues. A list of tissue-specific promoters currently being used in cancer gene therapy is given in Table 1. One of the main limitations of this type of promoter is that transgene expression may lead to cytotoxic effects in normal as well as tumour tissue derived from that same cell type. Therefore, the use of such promoters must be restricted to tissues in which damage is not critical for the survival of the host, for example, prostate, melanocytes, or thyroid. If the tissue/organ is critical, then the transgenes must be delivered directly to the tumour site to prevent normal tissue toxicity or be delivered with retroviruses which are less efficient at infecting nondividing slowly proliferating normal tissues, such as the liver.

Melanocyte-restricted expression

The use of tissue-specific promoters was pioneered by Vile and Hart in 1993, with the use of the tyrosinase promoter to target melanocytes/melanomas. Melanin biosynthesis is restricted to melanocytes, partly, as a consequence of transcriptional regulation of gene products, such as tyrosinase or tyrosinase-related protein 1, involved in this biochemical pathway. Vile and Hart demonstrated that small elements of the 5’ flanking regions of these two genes could drive reporter gene expression in murine and human melanoma cell lines in vitro and in vivo, but they could detect only low level expression in other cell types in vitro and no expression in Colo 26 tumours grown in vivo following direct injection of the transgenes [5]. They went on to demonstrate efficacy in vivo using the herpes simplex thymidine kinase (HSV-
Table 1. Tissue-specific promoters used in cancer gene therapy.

| Promoter                                  | Target tissue/tumour                                      | Reference               |
|-------------------------------------------|----------------------------------------------------------|-------------------------|
| Tyrosinase                                | Melanocytes/melanoma                                      | [5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18] |
| Prostate-specific antigen (PSA)           | Prostate                                                 | [19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33] |
| Prostate-specific membrane antigen (PSMA) | Prostate/also targets vascular endothelium of other tumours | [31, 34, 35, 36]       |
| Probasin                                  | Prostate                                                 | [28, 37, 38, 39, 40, 41] |
| Human glandular kallikrein (hK2)          | Prostate                                                 | [25, 37, 38, 42]       |
| Glial fibrillary acidic protein (GFAP)    | Glial/glioma                                             | [43, 44, 45, 46, 47, 48, 49, 50, 51] |
| Myelin basic protein (MBP)                | Glial and astrocytes/glioma                              | [43, 44, 52, 53, 54, 55] |
| Myelin proteolipid protein                | Glial/glioma                                             | [43, 44]               |
| Neural specific enolase                   | Neuronal/SCLC                                            | [48, 56]               |
| Neuronal specific synapsin 1              | Neuronal                                                 | [57, 58]               |
| Ncx/Hox11 L.1                             | Neural crest derived cells/neuroblastoma                 | [59]                   |
| Albumin                                   | Liver/hepatocellular carcinoma                          | [60, 61, 62, 64, 65, 66] |
| Surfactant protein B                      | Type II alveolar and bronchial cells/lung cancer          | [67, 68]               |
| Thyroglobulin                             | Thyroid/thyroid carcinomas                               | [69, 70, 71, 72, 73]   |
| Ovarian-specific promoter                 | Ovarian                                                  | [74, 75]               |

The tk/gancyclovir (GCV) combination, which gave a significant tumour growth delay following intratumoural injection of the tyrosinase-driven constructs and decreased metastatic potential in mice injected with melanoma cells expressing these constructs following treatment with GCV [6]. In a separate study, tissue-specific expression of IL-2, IL-4, and GM-CSF was also seen in vitro and in vivo [7]. As an extension to this work, retroviruses were developed containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of HSV-tk or IL-2 genes [8, 9]. Antitumour efficacy and tissue specificity were observed after intratumoural and IV delivery using localised and metastatic melanoma models [7]. Other studies have demonstrated antitumour efficacy using both retrovirus [10] and cationic liposomes [11] to achieve tyrosinase driven expression of cytokine deaminase (CD), which in turn catalyses the conversion of the nontoxic produg 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU). Adenoviral delivery of the murine tyrosinase promoter, introduced into the E1 region, has been used to drive melanoma-specific expression of the reporter gene β-galactosidase [12]. Both studies showed effective transcriptional targeting. More recently, tissue-specific elements of the tyrosinase promoter have been incorporated into more elaborate DNA constructs, that incorporate either a second tumour-specific promoter, cyclin A [13] for added specificity, or elements to help increase tyrosinase promoter expression [14]. As an extension to this, both targeted delivery and transcriptional targeting of melanoma cells via the tyrosinase promoter were combined in one study. Anionic liposomes carrying a peptide ligand for targeting α-β3-integrin receptors, commonly upregulated on malignant melanoma cells, were used in this instance for the transductional targeting [15]. These more elaborate combined approaches will be discussed in detail later as future perspectives.

Prostate-specific expression

Another well-characterised tissue-specific promoter is that of prostate-specific antigen (PSA). Prostate-specific antigen is expressed predominantly in the prostate and is transcriptionally upregulated by androgens. Pang et al [19] demonstrated that elements from the 5' region of this gene can drive reporter gene expression in the PSA-producing cell line, LNCaP, but not in cell lines of any other tumour [20]. In addition, a replication-competent adenovirus, CN706, has been developed with a selective toxicity for PSA-positive prostate cancer cells, using minimal enhancer/promoter constructs derived from the 5' flank of the PSA gene, to drive the E1A gene [21]. A single intratumoural injection of the virus destroyed large LNCaP tumours and abolished PSA production in mice. Gottoh et al [22] have developed an attenuated adenovirus which expresses HSV-tk from a 5837-bp fragment of the PSA promoter. This
promoter was active in both androgen-dependent and independent PSA-producing prostate cancer cells in vitro, and in prostate tumours in castrated hosts. Chimeric constructs which have also been engineered improved the activity and specificity of the PSA enhancer. Importantly, intravenous delivery of adenoviral constructs, with either duplication of the enhancer core or insertion of tandem copies of the proximal androgen response elements, not only showed enhanced activity and inducibility but also retained tissue discrimination for human LAPC-9 tumour xenografts [23]. Constructs utilising PSA promoter elements have also been developed to drive the expression of the sodium iodide transporter to concentrate radioiodine [24]. They have also been used to increase the expression of nitroreductase or CD allowing sensitisation of prostate cells to the prodrugs, CB1954 [25] or 5-FC, respectively [76]. PSA promoter driven transgenes have also been delivered using an HIV-1-based lentiviral vector [26] and liposomes [27].

Promoters of prostate-specific genes other than PSA are now being utilised. Prostate-specific membrane antigen (PSMA) is a type-2 membrane protein expressed in virtually all prostate cancers and their metastases. Moreover, unlike PSA, PSMA expression is upregulated by androgen deprivation. These advantages make PSMA a useful target for advanced prostate cancer therapy, especially in combination with conventional hormonal treatment. O’Keefe et al [34] have determined the most active regions of the PSMA enhancer and revealed a 1.6-kbp region which was active in driving prostate-specific CD expression, sensitising cells in vitro to 5-FC more than 50-fold compared to control cells. Furthermore, C4-2 prostate tumours grown in nude mice were eliminated by 5-FC when CD expression was induced by the PSMA promoter/enhancer [35]. This type of promoter will be particularly useful for patients who have undergone androgen ablation therapy and are suffering from a relapse of the disease.

Human glandular kallikrein (hK2) and PSA are related members of the human kallikrein gene family, however, unlike PSA whose expression displays an inverse correlation with prostate cancer stage and grade, hK2 is upregulated in higher grade and stage of the disease. Yu et al [37] identified an androgen-dependent and prostate-specific enhancer located between −3.4 and −5.2 kbp upstream of the hK2 transcription start site. A replication-competent adenovirus was constructed, CV763, in which the E1A gene was driven by the hK2 enhancer/promoter. Specificity for prostate tumours in vivo was impressive. More recently, a recombinant adenovirus expressing EGFP under the control of a triplicate hK2 enhancer/promoter led to robust tumour-restricted EGFP expression [38].

Probasin is another prostate-specific promoter, which has been used by many groups for transcriptional targeting of therapeutic transgenes. Steiner et al [28] used probasin to drive the expression of the *LacZ* reporter gene in a canine model following intraprostatic injection. They were able to demonstrate that, although adenovirus was detected in other tissue, lacZ mRNA could be detected by RT-PCR only in the prostate and not in other tissues. A small potent composite rat probasin promoter has been developed, ARR(2)PB, which is both androgen- and glucocorticoid-inducible [39]. When used to drive cell cycle-independent caspases, in an adenoviral system, it can lead to apoptosis in prostate cancer xenografts, but not in xenografts of other tumours, when the dimeric ligand AP20187 is delivered to trigger caspase activation [77]. More importantly, systemic delivery of a similar adenovirus, utilising the ARR(2)PB composite promoter to drive BAX expression, revealed no toxicity in the liver, lung, kidney, or spleen, but resulted in highly specific cytotoxicity in the prostatic cancer cell line LNCaP [40]. Lastly, a tumour-specific rather than prostate-specific promoter from the osteocalcin gene has shown a considerable promise in targeting prostate cancer bone metastases. This will be discussed in the next section.

**Glial-restricted expression**

A number of tissue-specific promoters have now been tested for targeting of gliomas. In 1993, Miyao et al [43], described 2.5 kbp, 1.3 kbp, and 1.5 kbp 5′ flanking regions of the mouse glial fibrillary acidic protein (GFAP) gene, myelin basic protein (MBP) gene, and myelin proteolipid protein (PLP) gene, respectively, which conferred specificity for glial cells. Following retroviral delivery, transcription was initiated more effectively in glia cells via the MBP promoter where the HSV-tk transgene sensitised cells to gancyclovir in both murine and human glioma cells [44]. GFAP promoter driven expression of HSV-tk and therapeutic efficacy for gliomas was demonstrated by other groups [45, 46]. The RL1 variant herpes simplex virus 1 (HSV-1) has also been engineered to target intracerebral tumours of glial and astrocyte origin by using the GFAP promoter. These viruses, 1774 and 1775, showed high levels of β-galactosidase expression specifically in astrocytes following intracerebral inoculation [47]. Replication-defective adenoviral vectors have also been engineered to contain either the GFAP promoter or the neuronal specific enolase promoter [48, 49]. Importantly, in the Morelli study, Fas ligand (FasL) transgene expression and induced-toxicity following IV delivery were restricted to glial tissue, unlike the noncell-type-specific CMV-driven viruses that induced acute liver haemorrhage with hepatocyte apoptosis. Tight control of transgene expression was therefore achieved following systemic delivery. In the Chen study, a repressible adenovirus was developed by driving expression of a tetracycline-controlled transactivator. This was the first glial-specific gene delivery system that allowed for repression of ectopic gene expression. More recently, an elegant liposomal delivery system has been developed; it incorporates both transport across the blood brain barrier following IV administration of a targeting ligand such as the peptidomimetic rat 8D3 mAb to the mouse transferrin.
receptor, and restricted expression to glial cells by the use of the GFAP promoter. This particular study demonstrates that tissue-specific gene expression in brain is possible after IV administration of a nonviral vector combined with gene targeting technology and glial-specific promoters [50]. Shinoura et al [52, 53, 54] have used the MBP promoter to drive expression of two apoptosis-related genes, BAX and caspase 8, selectively, in glialoma cells both in vitro, and in vivo using adenoviruses. Massive apoptosis was seen in glialoma cells only, demonstrating effective tissue specificity and good antitumour efficacy was observed in vivo.

As well as promoters that can target gliomas, a promoter that could be useful in targeting neuroblastomas has also been described. The human NCX gene, is a homologue of the murine neural crest homeobox (Ncx/Hox11L.1) gene, whose expression is restricted to a subset of neural crest-derived tissues. A 1.7-kbp fragment upstream showed preferential promoter activity in neuroblastoma cells and when linked to the HSV-tk gene caused increased sensitivity to gancyclovir [59]. The regulatory region of this gene may therefore be useful for neuroblastoma-specific gene therapy.

Liver-specific expression

The enhancer/promoter of the albumin gene is the only tissue-specific promoter that has been shown to preferentially target liver cells. The first demonstration of efficacy using this promoter was by Kuriyama et al [60]. When this promoter was delivered using a retrovirus, which is efficient only in dividing cells, β-galactosidase expression was restricted to hepatoma cell lines in vitro. When this retrovirus was injected via the spleen or directly into the liver, gene expression was observed only in dividing hepatocytes in partially hepatectomised mice, but not in nondividing hepatocytes in normal mice. These authors went on to show that the susceptibility of murine and rat hepatocellular carcinoma (HCC) cells, infected with retroviruses expressing HSV-tk under the control of the albumin promoter, were 100-fold more sensitive to gancyclovir than non-HCC cells. Systemic gancyclovir administration resulted in complete regression of retrovirus-infected HCC cells and significant inhibition of tumour growth even when only 5% of the cells were infected with retrovirus [61]. The albumin promoter has also been used to develop a retrovirus expressing the TNF-α, IL-2, and IL-3 genes [62, 63], an adenovirus expressing HSV-tk [64, 65] and a replication-competent herpes simplex virus, HSV G92A [66].

Thyroid-specific promoters

Thyroid cancer is a disease with a relatively good prognosis, but about 30% of the tumours dedifferentiate and may finally develop into highly malignant anaplastic thyroid carcinomas which are inaccessible to standard therapeutic procedures such as radioiodine therapy and thyroxine-mediated thyrotrophin suppression. Several gene therapy strategies are now available to target therapeutic genes to thyroid tissues using tissue-specific promoters. Zeiger first described the use of the thyroglobulin (TG) gene promoter for the selective targeting of thyroid cell lines. Nearly, 100% of thyroid carcinoma cells treated with an adenovirus expressing HSV-tk under the control of a TG promoter were killed by GCV compared to only 5% of control cells [69]. A retrovirus carrying HSV-tk under the control of the TG promoter also showed preferential GCV toxicity for malignant rat thyroid carcinoma cells compared to a normal rat thyroid cell line in vitro and in vivo [70]. Furthermore, systemic delivery of an adenovirus expressing thyroglobulin-driven HSV-tk did not induce luciferase activity in the liver or spleen, indicating that TG does not induce luciferase expression in non-TG producing tissues [71]. In addition, transfer of the HSV-tk gene driven by the TG promoter following administration of GCV is specifically cytotoxic to thyroid cells [71]. In order to address the issue that most poorly differentiated and anaplastic thyroid carcinomas have lost the ability to express the TG gene through loss of the thyroid transcription factor-1 (TTF-1), TTF-2, or Pax 8, Shimura et al infected thyroid cells with both adenoviruses expressing TTF-1 and adenoviruses carrying HSV-tk driven by the thyroglobulin promoter [72]. Cotransduction permitted 90% cytotoxicity in thyroid carcinoma cells lacking this transcription factor and normally unable to express the TG gene. A putative enhancer element for the TG gene has also been recently identified which appears to increase the TG promoter activity and specificity for thyroid cells. Interestingly, the TG promoter is also being used to target feline thyroid disease and neoplasia by selectively increasing expression of the nitroreductase gene allowing subsequent activation of a prodrug, CB1954 [73].

Several other novel tissue-specific genes have been used to target tumours in a tissue-specific manner, although only one or two reports are available. These include an ovarian-specific promoter, OSP-1, a 462-bp sequence that is a part of a retrovirus-like element specifically expressed in rat ovary [74]. The expression of HSV-tk under the control of this promoter significantly sensitised ovarian cancer xenografts (OVCAR) to GCV following delivery with a cationic lipid [75]. In addition, the promoter for surfactant protein B (SPB), whose activity is restricted to adult type II alveolar epithelial cells and bronchial epithelial cells, has been used to target both replication-deficient [67] and -competent adenoviruses by replacement of the E4 promoter [68]. This promoter showed good specificity for bronchial cancer cells in vivo.

TUMOUR-SPECIFIC PROMOTERS

Ideally, tumour-specific promoters should be highly active in tumour cells and have little or no activity in normal cells. Harrington et al [78] elegantly split this vast group of promoters into subgroups depending on
their discrete characteristics and for the purpose of this review this convention will be applied. Tumour-specific promoters can be described as (1) cancer-specific promoters, that is, specific for the malignant process, but showing no tissue specificity (2) tumour-type-specific promoters, that is, oncofoetal related with tissue specificity (3) tumour microenvironment-related promoters, that is, promoters which respond to the tumour microenvironment and physiology, for example, hypoxia and glucose regulated (4) tumour vasculature-related promoters, that is, promoters which are more active in the tumour vasculature rather than normal vasculature.

**Cancer-specific promoters**

One of the main obstacles to current cancer therapies is the lack of tumour specificity. Targeting gene expression specifically to tumour cells is therefore one of the most important goals of cancer gene therapy strategies. A common problem with the use of the tissue-specific promoters which were described in the previous section, is that transgene expression can also occur in the normal tissue and whilst some tissue damage may be acceptable in certain organs, in other organs such as brain, liver, and so forth, it could be catastrophic. There is probably only one gene, telomerase, that can be genuinely classified as cancer specific and whose promoter is being used to drive the expression of transgenes selectively in a wide variety of tumour cells.

Telomerase activation is considered to be a critical step in cancer progression because of its role in cellular immortality. Approximately 90% of human cancers possess active telomerase, whereas normal somatic tissues have either much lower or undetectable activity [79, 80, 81]. Human telomerase activity depends on the presence of both the RNA subunit (hTR) and the catalytic protein component (hTERT) [82]. For both genes there is a clear differential expression between normal and malignant cells. A number of studies have used these two promoters to drive transgene expression for therapeutic benefit. Pan and Koeneman [83] first described the use of the hTERT promoter in a retroviral system and combined it with a Cre/loxP site-specific recombination system to allow the killing of p53-negative tumour cells while sparing normal wild-type cells. Since then, a host of papers have reported the use of both promoters in several different tumour types in combination with several different transgenes. Bladder and liver tumour cell lines were targeted using both hTR and hTERT to drive expression of the diphtheria toxin A chain gene [84]. The glioma cell line, UVW, was targeted using the hTR promoter to drive expression of the noradrenaline transporter gene (NAT) where a 17-fold enhancement of the radionuclide [131]iodoiodobenzylguanidine uptake was reported resulting in complete sterilisation of tumour spheroids [85]. Gliomas were also the target for hTERT-driven expression of Fas-associated protein with death domain (FADD) or rev-caspase-6. FADD is a protein which induces apopto-

s sis in cells regardless of Fas expression on the cell surface and rev-caspase 6 induces apoptosis independent of initiator caspases. Subcutaneously implanted human gliomas treated with this construct were significantly reduced in volume compared to control tumours [86, 87, 88]. More recently, the apoptotic pathway was successfully targeted both in human tumour xenograft and syngeneic mouse UV-2237m fibrosarcomas, using Bax as a transgene, driven by the hTERT promoter [89, 90]. In a suicide gene therapy approach, hTERT was also used to drive expression of HSV-1 tk in an osteosarcoma xenograft model following intratumoural injection. Targeted delivery using this approach avoided the liver toxicity observed using a CMV driven construct following GCV administration. Finally, Keith's group [91] tested hTR and hTERT in a panel of 10 cell lines consisting of lung, colon, ovarian, bladder, and cervical origin, demonstrating the truly “cancer specific” nature of these promoters. The hTERT promoter appeared to have the superior activity in the telomerase-positive cell lines and when used to drive the nitroreductase gene to increase the activation of the prod

rug, CB1954, in two xenograft models, it showed even better antitumour effects (up to 97% reduction in tumour volume) than a CMV-driven construct [91]. These promoters clearly have a real potential in targeting a wide range of different tumour types.

**Tumour-type-specific promoters**

Certain types of tumour often overexpress genes of oncofoetal origin that are silent in normal tissue. The most well-characterised promoters of these tumour-specific genes are the carcinoembryonic antigen (CEA) and α fetoprotein (AFP), which are expressed in adenocarcinomas and hepatocellular carcinomas, respectively. There are also many other genes that are overexpressed in certain tumour types and, as such, their promoters are being utilised for transcriptional regulation of therapeutic genes.

**CEA**

The CEA promoter is active in a proportion of breast, lung, colorectal, and pancreatic cancers. The 5’ promoter sequences have been analysed and identified by reporter gene assays and have lead to high-level selective expression of transgenes in CEA-positive cell lines [92]. The CEA promoter has been used to drive CD expression [92, 93, 94], HSV-1 tk [95, 96, 97, 98, 99], BAX [100], and mammalian degenerin, a sodium ion channel gene, overexpression of which leads to sodium influx and cell bursting [101]. Importantly, CEA appears to be truly selective for tumour tissues in animal models as several reports have not detected transgene expression or related toxicities following systemic delivery of these constructs via tail vein injection [98] or intraperitonally [94]. Although a significant number of studies have shown that the CEA promoter is effective for selectively targeting tumour cells, there have been few studies which have demonstrated
truly significant in vivo antitumour effects possibly because of the low activity of the promoter. More recently, several studies have made use of a Cre recombinase/loxP system [102, 103, 104] or a GAL4 regulatory system [100], both of which significantly increased transgene expression by up to 100 fold, while maintaining tumour specificity. These strategies will be discussed in more detail later. Finally, Qiao et al [105] constructed an adenovirus containing a binary promoter system with a CEA promoter driving a transcription activator, which then activates a minimal promoter to express HSV-\(tk\). Importantly, in vivo dose-escalation studies demonstrated significantly reduced toxicity following intravenous administration of this construct and provide a proof of principle for the powerful enhancement of a weak promoter for effective tumour-restricted gene expression.

**AFP**

The \(\alpha\)-fetoprotein gene is normally expressed in foetal liver and is transcriptionally silent in adult liver. It is also expressed in around 70% of the hepatocellular carcinomas and its promoter has been used extensively to drive transgene expression for targeting these tumours. Studies have clearly shown that transgene expression is restricted to tumours that overexpress AFP and that transgene expression is less efficient in tumours with lower AFP levels. A variant 0.3-kbp promoter has also been developed with a G to A substitution at nucleotide −119; a point mutation responsible for hereditary persistence of human AFP. This promoter has proved particularly useful for transgene expression in low AFP producing hepatoma cells [106]. Ishikawa et al. have also shown that by placing the AFP promoter/enhancer in the reverse orientation to the long terminal repeats with a retroviral construct dramatically increases both HSV-\(tk\) transgene expression and GCV-mediated cytotoxicity in a HepG2 tumour in vivo [107]. The AFP promoter has also been used to drive CD [108], IL-2 [109, 110], diphtheria toxin A [111], and interestingly, a replication-competent adenovirus has been constructed using the AFP promoter to drive an attenuated E1B gene. Systemic delivery of this virus resulted in tumour-specific regression [112]. The AFP promoter activity can be weak, but it can be enhanced using Cre/loxP technology to increase transgene expression [113], a similar strategy to that applied to CEA.

**ErbB2**

ErbB2/HER2 is an oncogene that codes for a receptor tyrosine kinase that is overexpressed by transcriptional upregulation in approximately one third of breast and pancreatic tumours, and in a small proportion of other tumours. This promoter has been used to drive the expression of CD and when delivered using a retrovirus, CD expression and significant 5-FC-mediated cell death was observed only in ErbB2-positive cell lines [114, 115]. ErbB2-driven expression of a membrane receptor, murine gastrin releasing peptide, has also been used effectively to target breast cancer cell lines with a radiolabelled peptide [116]. More recently, studies to identify a minimal ErbB2 promoter were successful. Maeda et al [117] identified a 251 bp fragment (−213/+38) that could direct transcription of a luciferase reporter gene better than the SV40 immediate early promoter in breast cancer cells. When linked to the HSV-\(tk\) gene, increased sensitivity to GCV was observed in breast but not nonbreast cancer cell lines, and suppressed the growth of these lines in nude mice.

*MUC1/DF3*

The MUC1 gene encodes a high molecular weight mucin-like glycoprotein and is overexpressed at the transcriptional level in breast and cholangiocarcinomas. A 114 bp enhancer region has been identified that can modulate transcription from heterologous promoters [118]. DF3-positive breast cancer cell lines were more sensitive to GCV-mediated cell killing when the HSV-\(tk\) gene was delivered and driven by this enhancer. A replication-defective adenovirus containing this construct was subsequently developed and inhibition of tumour growth was observed in an intraperitoneal breast cancer metastases model [119]. This strategy could transfect and kill carcinoma cells within haematopoetic stem cell populations without causing associated normal tissue toxicity [120]. An adenovirus expressing BAX under the control of this promoter has also been constructed for targeting ovarian cancer cell lines expressing DF3. Transgene expression was restricted to tumour tissue in a nude mouse model and administration of the virus 2–3 days after tumour inoculation eradicated > 99% of tumour implants [121].

**Osteocalcin**

Osteocalcin (OC) is a noncollagenous bone matrix protein expressed at high levels in the neonate. It functions primarily in osteoblasts found in growing bone and is highly expressed in osteogenic sarcomas. Koeman et al [122] have also provided evidence of expression in ovarian, lung, brain, and prostate tumours (especially those showing androgen-independence). A phase I trial is now underway to target androgen-independent prostate cancer using an adenoviral construct expressing HSV-\(tk\) under the control of this promoter. Of all the transcriptional targeting strategies discussed so far, the use of the osteocalcin promoter has been tested thoroughly using systemic delivery. Matsubara et al. [123] have successfully constructed a replication-competent adenovirus using this promoter to drive E1a expression. They demonstrated that 100% of mice carrying prostate xenografts responded to systemic adenoviral delivery and more significantly 40% of mice were cured. Phase I/II trials are now being carried out using the same virus to target pulmonary metastases of osteosarcomas, following systemic delivery of this virus, which must pass through the lung before being sequestered in the liver [124].
Shirakawa et al. [125] also used an adenovirus to target osteosarcoma pulmonary metastases with an osteocalcin driven HSV-tk. In an established animal model, systemic delivery of these constructs via tail vein injection and subsequent intraperitoneal acyclovir treatment significantly decreased the number of tumour nodules in the lung, while significantly increasing the survival of these animals. Interestingly, because the osteocalcin promoter can also target bone stromal cells, which are important for supporting the growth of prostate tumour metastases, an adenovirus expressing HSV-tk under the control of this promoter was effective at destroying prostate cancer xenografts in both subcutaneous and bone sites [122]. It is quite clear that this promoter will be important for the treatment of both prostate and osteosarcoma, but it will be some time before we learn about its true specificity and any associated toxicities. Certainly, because this promoter is effective in androgen-independent prostate tumours, it will ultimately be more effective than the tissue-specific PSA promoter discussed in the last section. A clearer understanding of this promoter may help to increase specificity even further and Yeung et al have already identified elements important for prostate specificity, in particular, the elements important for androgen-independent specificity [126].

**L-plastin**

L-plastin is constitutively expressed at high levels in malignant epithelial cells, but is not expressed in normal tissue, except at low levels in haemopoetic cells. A replication-incompetent adenovirus has been constructed to express either LacZ or CD under the control of the human L-plastin promoter. High levels of expression of β-galactosidase were seen in breast, ovarian, and fibrosarcoma cell lines [127] and in explants of ovarian cancer cells from patients compared to normal mesothelial cells from surgical specimens [128]. A greater reduction in tumour size was seen when the adenovirus expressing CD under the control of the L-plastin promoter was injected into human ovarian tumour xenografts than when the CD was controlled by the CMV promoter. L-plastin may therefore be an effective promoter for targeting ovarian cancer.

**Midkine**

Midkine (MK) is a heparin-binding growth factor that is transiently expressed in the early stages of retinoic acid-induced differentiation of embryonal carcinoma cells. Many malignant tumours express high levels of MK mRNA or protein with no expression in human liver. This is important as adenoviruses have a natural tropism for liver and such promoters could be useful for preventing transgene expression and associated hepatotoxicity in the liver. Miyauchi et al. [129] examined the expression of MK in human oesophageal cancer cells. Positive staining with anti-MK antibody was found in 8 out of 14 tumour specimens, while the surrounding normal oesophageal tissues in these specimens were not stained. The 5′ flanking 2.3-kbp region of the MK gene was then used to drive the expression of HSV-tk, where expression conferred the sensitivity to GCV. Since then, an adenoviral vector has been constructed to express HSV-tk under the control of the MK promoter to target Wilm's tumour and neuroblastoma cell lines [130]. Importantly, systemic delivery of these constructs into mice resulted in much lower hepatotoxicities; by day 8 of systemic delivery, four out of five mice treated with an adenovirus expressing HSV-tk via a CMV promoter had died, whereas all the mice treated with the midkine adenovirus survived at least 10 days [131]. The midkine promoter has also proved useful for targeting ovarian cancer cells and pancreatic cells, as has the cyclooxygenase-2 gene promoter [132, 133].

**Other tumour-type-specific promoters**

Many other tumour-specific promoters have been utilised to target particular types and are listed in Table 2. Particularly interesting is the secretory leukoprotease inhibitor gene (SPL1) promoter for targeting cervical carcinoma cells [157], lung, breast oropharyngeal, bladder, endometrial, and colorectal carcinomas [158]. Yamamura et al. [170] have used the promoter from the human calponin gene, normally expressed in maturated smooth muscle cells and overexpressed in human soft tissue and bone tumour cells, to drive expression of ICP4, a major transacting factor for viral genes to produce a novel conditionally replicating herpes simplex virus. The viral treatment showed stable and significant inhibition of tumourigenicity with cures in four out of five mice harbouring synovial sarcoma, leimyosarcoma, and osteosarcoma cells, while sparing normal vascular smooth muscle cells. Chen and McCormick [172] report on a novel transcriptional targeting strategy for colon cancer. Since many colon cancer cells show mutations in either the adenomatous polyposis coli or β-catenin genes that lead to stabilisation of β-catenin and activation of downstream T-cell factor (Tcf) target genes, tcf promoter elements were used to control expression of an apoptosis gene, FADD, which appears to effectively and selectively kill colon cancer cells. The regulatory regions of the H19 gene, is differentially regulated in normal and cancer cells and has been linked to diphtheria toxin A or HSV-tk to successfully target syngeneic bladder tumours in vivo with no obvious systemic toxicity towards the host animals [171]. A 2.2-kbp 5′ flanking region of the human calretinin gene has been used to drive the expression of HSV-tk selectively in mesothelioma cell lines [174] and the human calcitonin promoter has been used to drive expression of HSV-tk in medullary thyroid carcinomas following systemic delivery by adenovirus without any evident toxicity [175, 176, 177]. The gastrin-releasing peptide gene promoter has been used to selectively control HSV-tk expression in small-cell lung cancer cells [167]; injection of an adenovirus containing this construct resulted in complete regression of lung
Table 2. Tumour-specific promoters.

| Promoter                  | Tumour target                                                                 | Reference |
|---------------------------|-------------------------------------------------------------------------------|-----------|
| Telomerase                | Lung, colon, ovarian, bladder, cervical, liver, glioma                       | [83, 84, 85, 86, 87, 91, 134, 135, 136, 137] |
| CEA                       | Colorectal, pancreatic, cholangiocarcinoma, breast, lung                     | [92, 93, 94, 95, 96, 97, 98, 100, 138, 139, 140, 141, 142, 143, 144] |
| Alpha feto protein (AFP)  | Hepatoma                                                                      | [64, 106, 107, 108, 145, 146, 147, 148, 149] |
| Erb B2                    | Breast, pancreatic, ovarian                                                  | [114, 115, 116, 117, 150, 151, 152] |
| DF3/MUC1                  | Breast, cholangiocarcinoma                                                   | [116, 118, 119, 120, 121, 153, 154] |
| Osteocalcin                | Prostate, ovary, lung, brain, osteoblasts                                    | [122, 123, 124, 125, 126, 127, 155, 156] |
| L-plastin                 | Ovarian, breast, fibrosarcoma                                                | [127, 128] |
| Midkine                   | Embryonal carcinoma; Wilm’s tumours, neuroblastoma, pancreatic, oesophageal | [129, 130, 131, 132, 133] |
| Secretory leukoprotease inhibitor (SLP1) | Lung, breast, oropharyngeal, bladder, endometrial, ovarian, colorectal, cervical | [157, 158] |
| Alpha lactalbumin         | Breast                                                                        | [159] |
| Myc-max                   | Breast, lung                                                                  | [140, 160, 161] |
| Somatostatin              | Malignant melanoma of soft parts                                             | [162] |
| Cox2                      | Ovarian, pancreatic, gastroin-testinal                                        | [132, 133, 163] |
| Ornithine decarboxylase   | Colon and neuroblastoma                                                       | [164] |
| Epithelial glycoprotein 2 (EPG2) | Carcinomas                                                                     | [165] |
| c-Myb-responsive promoters | Hematopoietic tumours                                                         | [166] |
| Gastrin-releasing peptide | Lung                                                                           | [167, 168] |
| Metallothionein           | Ovarian                                                                       | [169] |
| Calponin                  | Soft tissue and bone tumours                                                  | [170] |
| H19                      | Bladder                                                                       | [171] |
| Tcf                       | Colon                                                                          | [172, 173] |
| Calretinin                | Mesothelioma                                                                  | [174] |
| Calcitonin/calcitonin gene-related peptide | Thyroid/thyroid medullary cancer                                              | [175, 176, 177] |

Cell cycle-related

| Promoter   | Tumour | Reference |
|------------|--------|-----------|
| Cdc25C     | Melanoma | [178] |
| CyclinA    | Melanoma | [13, 178, 179] |
| Endoglin   | Endothelial cells | [179, 180] |
| IGF-1-R    | Tumours mutant for p53, cMyb or EWS/WT1 | [181] |
| E2F-1      | Glioma  | [182] |

tumour xenografts following IP administration of GCV [168]. Lastly, Vandier et al [169] have been successful in targeting cisplatin-resistant ovarian carcinoma cells which overexpress the metallothionein gene, a metal binding protein. The human metallothionein promoter was therefore used to drive expression of HSV-tk, resulting in marked sensitisation to GCV in the cisplatin-resistant cell lines compared to the cisplatin sensitive cells.

Cell cycle-related promoters

The expression of proliferation-associated genes is a hallmark of both cancer cells and tumour endothelial cells. The retinoblastoma tumour suppressor gene (RB), is a cell cycle-associated gene, which has the ability to repress E2F-responsive promoters, such as E2F-1. E2F-responsive promoters should therefore be more active in tumour cells relative to normal cells because of an excess of free E2F and loss of RB/E2F repressor complexes. Parr et al [182] have shown that adenoviral vectors, containing transgenes driven by an E2F-1 promoter, can mediate tumour-selective gene expression in vivo, allowing for eradication of established tumours. Significantly, less toxicity was seen with this adenovirus than standard constitutively regulated adenoviral constructs.
Table 3. Tumour environment-specific promoters.

| Promoter                       | Tumour target                               | Reference                        |
|--------------------------------|-----------------------------------------------|-----------------------------------|
| **Endothelial cell-specific promoters** |                                              |                                   |
| KDR/Flk-1                      | Sarcoma, ovarian, endothelioma                | [184, 185, 186, 187]               |
| Flt-1                           | Breast, gynaecological, teratocarcinoma       | [188]                             |
| E-selectin                     | Endothelioma                                  | [184, 186, 189]                   |
| von Willebrand factor (vWF)    | Endothelial cells                             | [190]                             |
| Preproendothelin-1             | Endothelial cells                             | [191, 192, 193]                   |
| VCAM-1                         | Endothelial cells                             | [186]                             |
| **Hypoxia-responsive promoters** |                                              |                                   |
| VEGF (HRE elements)            | Hepatoma                                      | [145, 194, 195, 196, 197]         |
| Erythropoetin (HRE elements)   | Brain                                         | [198]                             |
| Phosphoglycerate kinase 1 (HRE elements) | Fibrosarcoma                                  | [33, 199]                         |
| **Glucose-responsive promoters** |                                              |                                   |
| GRP78                          | Breast                                        | [198, 200, 201, 202, 203, 204, 205]|
| Hexokinase II                  | Lung                                          | [206]                             |

Muller’s group have published several papers where the cell cycle-related promoter, cyclin A or cdc25c, has been used in combination with a tissue-specific tyrosinase promoter to selectively target proliferating melanoma cells [13, 178]. These dual specificity promoters showed > 20 fold and > 50 fold increase in cell cycle-related and cell-type-specific regulation, respectively, and will be discussed in more detail later.

Finally, the insulin-like growth factor-1 (IGF-1) has a central role in normal cellular proliferation. Transcription of this gene is controlled by a number of tumour suppressors. On the other hand, a number of oncogenes, including mutant p53 and c-Myb and the fusion protein EWS-WT1 significantly stimulate promoter activity. This promoter may therefore be a good candidate for use in transcriptional targeting in cancer gene therapy protocols [181].

Promoters that respond to the tumour microenvironment and physiology

There are many aspects of the tumour microenvironment that are unique, and can be targeted with strategies that take advantage of genes upregulated in response to these environments. For tumours to grow, they must stimulate angiogenesis; this requires proliferation of endothelial cells, a process specific (in normal adults) to the tumour microenvironment. An additional bonus of this strategy is that vectors delivered systemically will have direct access to the proliferating endothelial cells of the tumour vasculature. Furthermore, specific genes are upregulated in proliferating endothelial cells whose promoters are attractive for targeting transgenes to the tumour vasculature. Secondly, because the tumour vasculature is often disorganised and inadequate, areas of low oxygen tension (hypoxia) are prevalent in malignant tumours [183]. Many genes transcriptionally upregulated in response to hypoxia are mediated by the inducible transcription complex, hypoxia-inducible factor-1 (HIF-1). HIF-1 binds to DNA motifs known as hypoxia response elements (HREs) within these genes. HREs can therefore be used to drive transgene expression specifically within areas of tumour hypoxia. It is extremely important to target this population of cells since they are highly resistant to other forms of treatment, such as radio and chemotherapy. Lastly, as well as oxygen starvation, tumours can also be deprived of glucose leading to the increased expression of genes involved in glucose metabolism. The promoters of these genes are therefore also being used to drive transgene expression specifically within a tumour. A list of tumour microenvironment and physiology-related promoters can be found in Table 3.

Endothelial cell-specific promoters

Over the past 10 years a number of genes have been reported to be upregulated in proliferating endothelium of tumour blood vessels. The endothelial-specific kinase insert domain receptor (KDR/flk-1) and E-selectin have been shown to be upregulated in tumour endothelium, and defined regions of these promoters have been used to drive TNF-α carried by a retroviral vector. A 10–11-fold increase in TNF-α expression within sEND endothelioma cells was observed compared to NIH-3T3 fibroblasts [184]. More recently, it was demonstrated that the KDR/flk-1 promoter, is not only endothelial cell-specific, but also active in two human ovarian cancer cell lines where CD expression sensitised these cells to 5-FC both in vitro and in vivo [185]. E-selectin expression is very low in normal adult capillaries, but is significantly elevated in newly formed tumour vessels. It has been shown that the E-selectin promoter is also activated by TNF-α, generating a 30-fold increase in transgene expression compared...
to untreated cells. Furthermore, endothelial cells exposed to tumour-conditioned medium as an in vitro simulation of the tumour microenvironment resulted in even higher induction of transgene expression [189].

Flt-1, a receptor for vascular endothelial growth factor (VEGF), is known to display dysregulated expression in both tumour vasculature and tumour cells per se, and adenoviral vectors containing transgenes under the control of the flt-1 promoter achieve very low levels of toxicity in normal liver. This is important, as this is the major organ responsible for blood clearance of adenoviruses and most at risk from inadvertent transgene-related toxicity. Bauerschmitz et al [188] have shown that the flt-1 promoter is useful for the transcriptional targeting of adenoviruses to teratocarcinomas.

The promoter of human preproendothelin-1 has been used to generate a retrovirus that demonstrates endothelial-specific expression of the β-galactosidase gene [191, 192]. An adenovirus containing the preproendothelin-1 promoter driving luciferase expression has also been constructed. Following systemic injection, higher transgene expression was seen using this promoter rather than a CMV promoter, resulting in a high level of activity specifically in the new vasculature of primary tumours and lung metastases, with the highest level in the angiogenic endothelial cells of the metastasis [193]. However, an impediment to the use of the preproendothelin-1 promoter may be that it is also active in some epithelial cells [207], compromising its vascular targeting specificity.

The promoter for human von Willebrand factor (vWF) has also been used to drive transgene expression selectively in proliferating endothelial cells [190, 208]. Both reports emphasise that although this promoter is very weak, it appears to be highly selective for endothelial cells and is effective at suppressing endothelial cell growth when driving the HSV-tk gene in the presence of GCV. Furthermore, a novel strategy has been developed to enhance this promoter > 14–100 fold while maintaining > 30–100 fold specificity and will be discussed in more detail later [208]. Nettelbeck also tested the PECAM-1, endoglin, P-selectin, and KDR promoters, but vWF promoter was clearly the most specific for endothelial cells.

### Hypoxia-responsive promoters

Hypoxia response elements (HREs) found within the hypoxia-responsive genes of vascular endothelial growth factor (VEGF), erythropoietin (Epo), and phosphoglycerate kinase-1 (PGK-1), have been tested for their use in cancer gene therapy. Shibata et al examined the HREs of human VEGF and Epo and found high inducibility of both in mammalian cells, while only the HREs from the VEGF promoter were active in murine cells, and then to a lesser extent than in human cells. In addition, the introduction of multiple copies of the HRE and an E1B minimal promoter improved the hypoxia responsiveness [194]. Shibata then tested other HRE promoter combinations and found that 5HREs and a CMV minimal promoter exhibited the most effective hypoxia response (over 500 fold) when compared to an intact CMV promoter [195]. In addition, significant antitumour effects were achieved with intraperitoneal injections of the prodruk, CB1954, in tumours that expressed bacterial nitroreductase (NTR) constitutively or via this hypoxia-inducible promoter. Furthermore, respiration of 10% O₂ increased tumour hypoxia in vivo and enhanced the antitumour effects [196]. The HREs of the mouse VEGF gene have also been used to construct a retroviral vector expressing HSV-tk and tumours expressing this construct regressed following administration of GCV [197]. Dachs et al [199] have successfully utilised HREs from the PGK-1 gene and have shown that it is active in hypoxic tumour cells in vivo and Ruan et al [198] have constructed an adeno-associated virus carrying HREs from the Epo gene that can increase gene expression in brain tumour cell lines, under anoxia, by 79–110 fold. Combinations of both hypoxia and tumour/tissue-specific elements are now being developed to increase specificity for hypoxic tumour cells [145, 150, 186, 209]. These will be discussed in more detail later.

### Glucose-responsive promoters

The glucose-regulated protein GRP78 functions as a molecular chaperone and can bind to malformed proteins and unassembled complexes. They are induced in response to low glucose, hypoxia, acidic pH, or oxidative stress, which are hallmark features of solid tumours. The use of these promoters for cancer gene therapy was first proposed by Lee's group [200]. This group has fully characterised the use of this promoter in several tumour systems. A truncated rat GRP78 promoter with most of its distal basal elements removed drove high level expression in a murine fibrosarcoma model [201] and when GRP78 was used in a retroviral system to drive HSV-tk, HSV-tk expression levels were much higher [202] in tumours in vivo than cells in vitro, resulting in complete tumour eradication with no recurrence of tumour growth. Similarly, impressive results were obtained in a murine mammary adenocarcinoma cell line (TSA) in syngeneic, immune-competent hosts [203]; in addition, immune memory was induced in these hosts with this system. Finally, Luna et al [204] have used photodynamic therapy (PDT) to activate the GRP78 promoter, since this modality generates cytotoxic singlet oxygen species, which are potent activators of this promoter. Inducible expression of HSV-tk was observed after PDT in stably retroviral-transduced mouse mammary carcinoma cells (TSA), and enhanced tumouricidal activity was seen. The GRP78 promoter is, therefore, also inducible and can function as a molecular switch following exposure to PDT.

Hexokinase II is also overexpressed in solid tumours, partly due to elevated glucose catabolism in rapidly proliferating cells. Hexokinase II catalyses the first committed step of glycolysis and is overexpressed in some tumours since it is no longer responsive to the physiological
**Table 4. Exogenously controlled inducible promoters.**

| Promoter                      | Tumour target                      | Reference                      |
|-------------------------------|------------------------------------|--------------------------------|
| **Radiation-inducible promoters** |                                    |                                |
| Egr-1 and CArG elements       | Glioma, hepatocellular carcinoma, soft tissue sarcomas | [209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221] |
| Waf-1                         | Murine fibrosarcoma                | [222, 223]                     |
| RecA                          | Clostridia                         | [224, 225]                     |
| c-IAP2                        | Colon                              | [226]                          |
| **Heat-inducible promoters**  |                                    |                                |
| HSP70B                        | Breast, melanoma, and prostate     | [227, 228, 229, 230, 231, 232, 233, 234] |
| Gadd 153                      |                                    | [235]                          |
| **Drug-inducible promoters**  |                                    |                                |
| MDR-1                         | Breast, colon                      | [236, 237, 238]                |
| Tetracycline inducible        | Breast, melanoma, brain, glioma, prostate | [49, 146, 239, 240, 241, 242, 243, 244, 245, 246, 247] |
| Rapamycin inducible           | Fibrosarcomas                      | [248]                          |
| Tamoxifen-inducible estrogen response elements | Breast | [150, 249, 250] |

EXOGENOUSLY CONTROLLED INDUCTIBLE PROMOTERS

The use of tissue/tumour-specific cellular promoters to restrict transgene expression usually results in constitutive expression in the target tissue. However, in many situations it might be preferable to exogenously regulate the duration and level of expression. A list of exogenously controlled inducible promoters currently being used for cancer gene therapy purposes can be found in Table 4.

**Radiation-inducible promoters**

Radiation therapy is one of the main strategies used to treat solid tumours and although successful in some cases, there is the potential for enhancing radiation effects by combining with other agents such as gene therapy. Radiation-mediated gene therapy exploits the fact that as well as the cell killing effect, radiation will also activate transgenes which are driven by a radiation-inducible promoter. Confinement of transcription to the radiation field should be achievable by either using conformal, interstitial, or brachytherapy and by targeted delivery of radioisotopes. The cellular response to ionising radiation includes the transcriptional activation of a variety of genes, for example, c-jun, NFB, EGR1, and p21WAF1/CIP1, to name but a few. However, although numerous radiation-inducible genes and proteins have been identified, relatively few radiation-inducible promoters/enhancers have been fully characterised.

Datta et al [251] identified a sequence of the EGR-1 gene that confers radiation inducibility. This sequence, CC(A+T rich)GG, is known as the radiation-responsive CArG element. In vitro studies, using the CArG, elements of the EGR1 promoter have demonstrated a dose-dependent expression of reporter gene activity of up to 28 fold following radiation exposure (0–20 Gy) [210]. However, at therapeutically relevant doses of radiation (2 Gy) only a 3-fold increase in reporter gene activity was achievable [211]. The thymidine analogue 5-iodo-2′-deoxyuridine radiolabelled with the Auger electron-emitter iodine-125 also activated the promoter and resulted in increased β-galactosidase activity in the 9L gliosarcoma tumour model in vivo. A number of studies have used CArG elements to drive expression of TNF using liposomes [212], a haemopoetic cell carrier [213] and adenovirus [214, 215, 216]. These studies have led to clinical trials where an adenovirus carrying TNF driven by CArG elements of the Egr-1 promoter are injected intratumourally into patients with soft-tissue sarcomas, followed by irradiation [217]. Enhanced antitumour effects were also observed when the Egr-1 promoter was combined with HSV-tk [210, 252]. Tumours regressed significantly after GCV and radiation in comparison to GCV alone. Furthermore, tumour regrowth did not occur when GCV treatment was withdrawn. As well as being radiation-inducible the Egr-1 promoter was tumour-specific for hepatocellular carcinomas whereas its expression was barely detectable within normal liver [210]. It
was evident from some of these papers that reporter gene expression was detectable in nonirradiated cells, which could limit its use in combination with cytotoxic agents. Wechselbaum et al [218] are also developing a herpes simplex virus (HSV-1) that is induced to proliferate within the tumour volume following ionising radiation exposure. Finally, Marples and Scott are developing a novel molecular switch using CArG elements derived from this promoter, in combination with a Cre/loxP site-specific recombination system of the P1 bacteriophage, to generate high level and constitutive expression of transgenes following activation by therapeutically relevant radiation doses [209, 219, 253]. This system will be discussed in more detail later.

The promoter of the P21<sub>WAF1/CIP1</sub> gene is also radiation-sensitive and its activation is also increased in tumour cells [254, 255, 256, 257, 258, 259, 260, 261]. Interestingly, expression appears to be independent of p53 status in a variety of tumour types [257, 262, 263]. Furthermore, there have been evidence that this promoter is also highly active following exposure of cell in vitro to hypoxia (unpublished data, 2002). This promoter therefore, may have several layers of specificity, that is, tumour-, radiation-, and hypoxia-specific. Research in our laboratory has shown that WAF-1 can successfully drive expression of inducible nitric oxide synthase which leads to the generation of the vasoactive, cytotoxic, and radiosensitising product, nitric oxide (NO), close to therapeutically relevant doses. As well as causing significant vasorelaxation in isolated arteries [222], it also caused abundant apoptosis in a murine fibrosarcoma model and a highly significant tumour growth delay in vivo when used in combination with 20 Gy radiation [223]. This promoter is also being used to drive expression of cytochrome P450 enzymes to increase the activation of the bioreductive drug, AQ4N [264, 265].

Radiation-inducible bacterial promoters have also been used such as RecA, delivered using the anaerobic pathogenic bacterium, clostridia, as a gene transfer system to target anoxic areas within tumours. Significant increases in β-galactosidase activity and TNF-α secretion was seen following 2-Gy irradiation [224, 225, 266]; fractionation of the radiation dose lead to repeated gene induction.

Lastly, a retrovirus gene trap screening identified c-IAP2 as an X-ray-inducible gene with radiation-sensitive NFκB binding sites. Construction of a plasmid with four tandem repeats of the NFκB binding site driving the expression of the apoptotic suicide gene BAX, resulted in significant cell kill following a therapeutically relevant dose of 2-Gy X-rays [226].

**Heat-inducible promoters**

Hyperthermia is known to improve the response of tumours to radiation and chemotherapeutic treatment [267]. The cellular response to hyperthermia is associated with the synthesis of heat shock proteins (HSP). Strategies are now being developed to combine hyperthermia with gene therapy by using the promoter of the HSP70B gene to selectively activate therapeutic transgenes following hyperthermia treatment, thereby controlling the location, duration, and level of expression of the therapeutically selective promoter. MRI-guided ultrasound is also being used to accurately focus gene activation [227]. The HSP70B promoter has been used to drive expression of TGF-β in an adenoviral construct [268]; HSV-tk, where sensitivity to GCV in a mouse mammary cancer cell line was increased more than 50,000 times [228]; HSV-tk/cytosine deaminase fusion gene and a replication-competent E1B-attenuated adenoviral vector [229]; and IL-12 in combination with radiation [230, 231]. The HSP70B promoter appears to be highly active and a 200–950-fold increase in reporter gene expression was observed when additional heat shock elements (HSE) were introduced to the HSP70 promoter with a 1–2°C decrease in the activation temperature [232]. Two very elegant constructs have now been developed which incorporate elements from the HSP70 promoter. Emiliusen et al and Lipinski et al have developed constructs which incorporate effective feedback loops which can enhance transgene expression and immune response [14] or inhibit transgene expression in normal cells expressing wild-type p53 [173]. These will be discussed in more detail later. Interestingly, electromagnetic fields have been reported to activate the HSP70 promoter and could possibly be used as switches to regulate transgenes for cancer gene therapy purposes [269]. This has already been achieved with another stress-inducible promoter, Gadd153. The promoter from this gene was placed upstream of the TNF-α gene and delivered using magnetite cationic liposomes (MCLs). In nude mice, these constructs induced cell death throughout much of the tumour area on heating under an alternating magnetic field as a result of a 3-fold increase in TNF-α production compared with that of a nonheated tumour [235].

**Drug-inducible promoters**

As already mentioned many tissue/tumour-specific promoters are often weak and are therefore less effective than constitutive promoters. Much work has therefore focused on developing promoters which are both strong and regulatable exogenously. The use of tetracycline (tc)-responsive promoters is probably best researched. Two systems exist; the allostERIC-off system or the allostERIC-ON system which have been described in detail by Harrington et al [78]. A tc inducible promoter has been used to drive expression of HSV-tk in breast carcinoma cells and increased the IC50 for GCV by 50 fold, although bystander effects were not enhanced [239]. Both IL-2 and IL-1β converting enzyme (ICE) have been shown to be tightly regulated, respectively, in human melanoma cells [240] and in a rat brain tumour model [241] in vivo using a similar approach. However, the real beauty of this system has been to selectively regulate transgene expression in...
certain tissues by combining with tissue/tumour-specific promoters. A replication-incompetent adenovirus, which has the glial fibrillary acidic protein coupled to a minimal CMV promoter, has been constructed to drive expression of a tc-controlled transactivator. High levels of expression were reported in cells of glial origin and expression was tightly controlled by the addition of tc. This system is both glial-specific and allows for repression of ectopic gene expression [49]. Both a parvovirus and an adenovirus have been constructed to combine cell-type specificity with high-level regulated expression for prostate tissues using the ARR2BP promoter [57] or for hepatoma cells using a liver-specific promoter [146]. In a similar study, Rubinchik et al [242] have placed the tc transactivator gene under the control of the ARR2BP promoter and an FASL fusion gene under the control of a tc responsive promoter, within a single construct. Not only is the expression of this apoptotic related gene FASL restricted to prostate cancer cells and is regulatable by the tc analogue, doxycycline, but also, in vivo studies confirmed that systemic delivery of this vector was well tolerated at doses that were lethal for the FASL controlled by a CMV promoter. Overall, tc promoters show high-level inducibility compared to other inducible promoters and when combined with other tissue- and tumour-specific elements, they can be highly inducible and specific.

Dimerisation switch-on systems are also being developed, which make use of the immunosuppressive agent, rapamycin, and again this area has been reviewed by Harrington et al [78]. Rapamycin has been used to control regulation of adenoviral vectors where inhibition of tumour growth was seen following subcutaneous injection into the human fibrosarcoma, HT1080 [248].

As well as tc, there is now much interest in the use of estrogen response elements (EREs) which are responsive to estrogens and can be controlled by antiestrogens, such as tamoxifen. EREs have been used to drive expression of the E1a and E4 units in response to estrogens-generating conditionally replicative adenoviruses, selective for ER-positive breast cancer cells, which can also be modulated by the addition of tamoxifen [249]. When these EREs were combined with hypoxia response elements, these viruses can kill ER-positive breast cancer cells or cells growing under hypoxic conditions [150].

Lastly, a series of papers have described the use of the multidrug resistance (mdr1) gene promoter which harbours drug-inducible response elements to drive expression of a reporter gene [270] and TNF-α within a retroviral construct both in vitro in mammary and colon carcinoma cell lines [271] and in vivo in MCF-7 mammary xenografts [236]. Chemotheraputic regulation by doxorubicin or vincristine showed a 25-fold increase in TNF-α secretion within the xenografts and was more effective in inhibiting tumour growth than constitutively TNF-α-expressing vectors. More recently, Walther et al [237] have shown that the mdr1 promoter also harbours heat-inducible elements.

### STRATEGIES FOR ENHANCING THE EFFICIENCY OF WEAK TISSUE/TUMOUR-INDUCIBLE PROMOTERS

The transcriptional activity of the tissue-specific elements used as promoters for gene therapy is often too weak to generate adequate concentrations of transgene product in target cells. The dilemma is how to achieve high levels of transgene expression without compromising specificity. As mentioned previously, several elegant strategies have been developed which combine both inducible and tissue/tumour-specific elements, thereby increasing transcriptional activation while allowing tissue specificity to be retained. Furthermore, other systems have been developed which are tissue-specific but also highly active by encouraging positive feedback loops incorporating strong transcriptional activators.

In one approach, a weak tissue-specific promoter (vWF or gastrointestinal-specific sucrose-maltase) initiates transcription of both the transgene and a gene encoding a VP16-LexA fusion protein (Figure 2). This protein, in turn, interacts with LexA binding sites inserted upstream of the tissue-specific promoter, leading to transcriptional activation and enhanced transcription. Repeated cycles of this amplification lead to very high levels (14–100 fold) of tissue-specific expression [208]. An alternative strategy using a GAL4/VP16 fusion protein to enhance the weak tumour-specific CEA promoter achieved similar amplification of the reporter genes LacZ or GV16 [100]. This concept has been further developed by using a tissue-specific promoter (PSA) to drive expression of GAL4 derivatives fused with up-to-4 VP16 activation domains. By incorporating up-to-3 GAL4 binding sites upstream of the reporter gene (firefly luciferase) 800-fold amplification was achieved [272].

The Cre/loxP system offers a different approach to the enhancement of tissue-specific promoter activity (Figure 3). Target cells are transfected with a plasmid incorporating the therapeutic transgene separated from a strong constitutive promoter by a “stop” cassette enclosed by two loxP sites. Cotransfection with a site-specific Cre gene driven by the tissue-specific promoter generates Cre, which excises the stop cassette, bringing the therapeutic transgene under the control of the constitutive promoter [113]. This system has been used to achieve therapeutic levels of transgenes in mouse tumours in vivo with a high degree of tissue specificity. CEA-driven expression of Cre together with expression of lox-HSV-tk caused significant suppression of tumours in mice treated with GCV, without significant side effects [99, 104]. CEA-driven expression of Cre also achieved cytotoxicity in tumours in mice transfected with cytosine deaminase and dosed with the 5-FU precursor, 5-FC, and this was reflected in enhanced overall survival. Diphtheria toxin (DT) has also been used therapeutically in growth hormone (GH)-producing pituitary tumours; the DT gene was activated via the Cre/loxP system driven by the GH promoter [273]. Cre/loxP has also been used to increase HSV-tk transgene
Therapeutic gene (TG) 
Tissue- or tumour-specific inducible promoter 1 
VP16-LexA binding sites 
VP16-LexA 
VP16-LexA binding sites 
Tissue- or tumour-specific inducible promoter 2 
Therapeutic gene (TG)

Figure 2. Schematic outline of a positive feedback loop utilising VP16/LexA to enhance weak promoters. Transcription is initiated by the cell-type-specific promoter in target cells which leads to expression of the VP16/LexA fusion protein. The VP16/LexA protein then interacts with the LexA binding sites upstream of a possible second cell-type-specific promoter leading to transactivation and thus enhancement of transcription. Alternatively, the VP16/LexA fusion protein could be expressed along with the transgene expressed via an IRES. Adapted from Nettelbeck et al [179].

expression following expression of Cre via the radiation-inducible CArG elements [209, 219].

Another approach that has a potential for tumour-specific activation incorporates specificity for mutated p53 [173]. In this study, a double recombinant adenovirus consisting of two independent expression cassettes was constructed; one controlled expression of the E. coli nitroreductase gene via an hsp70 promoter containing LacI binding sites, which was capable of binding a p53-inducible lac repressor, incorporated into the second expression cassette. This resulted in growth inhibition of human tumour xenografts with mutated p53 following exposure to the prodrug, CB1954, but not in tumours with wild-type p53 status.

Lastly, high-level tissue-specific expression of a directly cytotoxic protein, gibbon ape leukemia virus hypofusogenic envelope protein (GALV-FMG), has been achieved in melanoma cells by elegantly driving both GALV and the gene for heat shock factor 1 (HSF-1) from a human tyrosinase promoter, preferentially activated in melanoma cells [14]. Promoter activity initiates low-level expression of the toxic transgene, but also HSF-1, which binds to a heat shock binding element upstream of the tyrosinase promoter. This enhances promoter
FIGURE 4. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporate an immunostimulatory component. A weak tissue- or tumor-specific promoter will initially express the therapeutic transgene (TG) at low levels, however coexpression of the heat shock transcription factor (HSF-1) will activate the heat shock element (HSE) causing progressively increased TG and HSF-1 expression via a positive feedback loop. In addition, the expression of HSF-1 causes an immune response. Adapted from Emiliusen et al [14].

activation and completes the transcriptional feedback loop (Figure 4). This strategy has achieved long-term eradication of melanomas in mice [14].

CONCLUSIONS AND FUTURE PERSPECTIVES

The ultimate goal of all currently used cancer therapy is to target damaging events to tumour cells while sparing normal tissues sufficiently that they can recover to an adequate functional level; this applies equally to gene therapy. However, while conventional therapies rely on one, or at the most two, targeting characteristics such as spatial deposition, biochemical pathway specificity, or cellular proliferation, there is no theoretical limit to the number of elements that can be incorporated into a gene therapy strategy to confer tumour specificity. There is also the potential for controlling temporal expression of transgene products in tumours much more precisely than the concentration of conventional anticancer agents.

The first opportunity for targeting specificity is at the level of vector delivery. There is currently an immense amount of research activity in this area (beyond the scope of this review) reflecting the recognition that advances in this process are critical to unleashing the potential of all the recent developments in transcriptional control. Direct injection systems have been important in providing the proof of principle for several gene therapy strategies, but however sophisticated these may become, the number of accessible sites will always be limited and perhaps more importantly the crucial problem of disseminated disease cannot be addressed.

As detailed in this review, the possibilities for targeting via transcriptional control are endless. It is unlikely for most cancers that any one promoter will offer the ideal combination of interrelated characteristics: high level specificity to endogenous or exogenous factors, silence in the absence of these factors and sufficient strength to induce the therapeutic transgene many fold. In any event, the use of a single promoter/transgene combination fails to exploit one of the main advantages of gene therapy: the ability to custom design, even within a single plasmid, a combination of diverse elements that confer exquisite spatial and temporal specificity for an individual tumour type. It may even be possible using gene/protein array technology to tailor this specificity to an individual patient's tumour. It could be envisaged that promoters specific to the tumour tissue type could be combined with factors inducible by the tumour microenvironment and/or exogenous control elements (eg, radiation). This has already been successfully achieved in vivo by combining cell cycle and tyrosinase promoters [179], HREs and KDR/E-selectin promoters [186], and HREs and the AFP promoter [145]. Furthermore, these could be combined with elements incorporating strong promoters/enhancers in positive feedback loops giving progressively stronger and more specific transgene expression [14, 179] or by using a Cre/loxP system [274]. The packaging of such complex constructs, ideally within a single construct, will
require a more thorough understanding of the control domains from individual promoters such that multiple copies of the elements that confer tumour specificity can be incorporated while eliminating those sequences that permit expression in nontarget tissues. A vital issue when considering the clinical application of any gene therapy protocol is the basal expression of the transgene. Many of the papers discussed in this review have failed to adequately assess basal-level expression in other tissues following systemic delivery in an appropriate in vivo model. Highly sensitive systems now exist for assessing promoter leakiness in vitro and recent developments in imaging technology have permitted whole animal detection of fluorescent reporter gene products in small rodents. Although this technology is theoretically applicable in man, considerable caution must be exercised in extrapolating from animal data. It is likely in early trials that transgene activation by a given promoter combination will need to be assessed using a nontoxic reporter gene, particularly where tissue-specific promoters are to be used. This use of a surrogate marker is an additional and important advantage of gene therapy over conventional chemotherapy that can be applied even at the level of the individual patient.

Finally, the therapeutic transgene product will usually be an enzyme, so the opportunity arises to achieve additional specificity at the level of enzyme biochemistry or enzyme product characteristics. For example, reductive enzymes can metabolise bioreductive produgs, such as AQ4N or tirapazamine, specifically in a hypoxic environment thereby adding an additional layer of tumour specificity even after transductional and transcriptional targeting. A similarly enhanced specificity can be achieved, where the final product of the enzyme specifically sensitises hypoxic tumour cells. Alternatively, a powerful approach for tight regulation has been to make the activity of the apoptotic target gene, E2F1, tamoxifen-dependent by fusing it to the ligand-binding domain of the estrogen receptor; massive apoptosis was seen upon activation by tamoxifen.

The rate of development of gene therapy over the past decade has been dramatic and if this continues, it is reasonable to speculate that the next decade will see a level of anticancer efficacy combined with normal tissue sparing that few small molecules have yet achieved and with the current advances in systemic gene delivery this is a very real possibility. By combining the very best of cancer gene therapy strategies with current chemotherapy and radiotherapy treatment regimens, real patient benefit with reduced toxicities should be achievable.

ACKNOWLEDGMENT

The authors thank Prof Stephanie McKeown for her critical reading of this manuscript.

REFERENCES

[1] Maron DJ, Choi EA, Spitz FR. Gene therapy of metastatic disease: progress and prospects. Surg Oncol Clin N Am. 2001;10(2):449–460.
[2] Brown MD, Schatzlein AG, Uchegbu IF. Gene delivery with synthetic (non viral) carriers. Int J Pharm. 2001;229(1-2):1–21.
[3] McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer. 2001;1(2):130–141.
[4] Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta. 2002;1575(1-3):1–14.
[5] Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 1993;53(5):962–967.
[6] Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 1993;53(17):3860–3864.
[7] Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 1994;54(23):6228–6234.
[8] Vile R, Miller N, Chernajovsky Y, Hart I. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther. 1994;1(5):307–316.
[9] Diaz RM, Eisen T, Hart IR, Vile RG. Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J Virol. 1998;72(1):789–795.
[10] Cao G, Zhang X, He X, Chen Q, Qi Z. A safe, effective in vivo gene therapy for melanoma using tyrosinase promoter-driven cytotoxic deaminase gene. In Vivo. 1999;13(2):181–187.
[11] Siders WM, Halloran PJ, Fenton RG. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 1996;56(24):5638–5646.
[12] Jerome V, Muller R. Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells. Hum Gene Ther. 1998;9(18):2653–2659.
an immunostimulatory component. Gene Ther. 2001;8(13):987–998.

[15] Nahe T, Muller K, Fahr A, Muller R, Brusselbach S. Combined transductional and transcriptional targeting of melanoma cells by artificial virus-like particles. J Gene Med. 2001;3(4):353–361.

[16] Vile RG, Hart IR. Targeting of cytokine gene expression to malignant melanoma cells using tissue-specific promoter sequences. Ann Oncol. 1994;5(suppl 4):59–65.

[17] Hart IR. Tissue specific promoters in targeting systemically delivered gene therapy. Semin Oncol. 1996;23(1):154–158.

[18] Bazzone F, Regalia E. Triggering of antitumor activity through melanoma-specific transduction of a constitutively active tumor necrosis factor (TNF) R1 chimeric receptor in the absence of TNF-alpha. Cancer Res. 2001;61(3):1050–1057.

[19] Pang S, Taneja S, Dardashti K, et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther. 1995;6(11):1417–1426.

[20] Lee CH, Liu M, Sie KL, Lee MS. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer. Anticancer Res. 1996;16(4A):1805–1811.

[21] Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57(13):2559–2563.

[22] Gotoh A, Ko SC, Shirakawa T, et al. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol. 1998;160(1):220–229.

[23] Wu L, Matherly J, Smallwood A, et al. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther. 2001;8(18):1416–1426.

[24] Spitzweg C, Zhang S, Bergert ER, et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 1999;59(9):2136–2141.

[25] Latham JP, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 2000;60(2):334–341.

[26] Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther. 2001;8(9):628–635.

[27] Suzuki S, Tadakuma T, Kunitomi M, et al. Liposome-mediated gene therapy using HSV-TK/ganciclovir under the control of human PSA promoter in prostate cancer cells. Urol Int. 2001;67(3):216–223.

[28] Steiner MS, Zhang Y, Carraher J, Lu Y. In vivo expression of prostate-specific adenoviral vectors in a canine model. Cancer Gene Ther. 1999;6(5):456–464.

[29] Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54(20):5474–5478.

[30] Spitzweg C, O’Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 2000;60(22):6526–6530.

[31] Gong MC, Chang SS, Watt F, et al. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Mol Urol. 2000;4(3):217–222; discussion 223.

[32] Suzuki S, Tadakuma T, Asano T, Hayakawa M. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations. Cancer Res. 2001;61(4):1276–1279.

[33] Zhang S, Gu J, Yang NS, et al. Relative promoter strengths in four human prostate cancer cell lines evaluated by particle bombardment-mediated gene transfer. Prostate. 2002;51(4):286–292.

[34] O’Keefe DS, Uchida A, Bacich DJ, et al. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate. 2000;45(2):149–157.

[35] Uchida A, O’Keefe DS, Bacich DJ, Molloy PL, Heston WD. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/ enhancer: a potential alternative approach to androgen deprivation therapy. Urology. 2001;58(2)suppl 1:132–139.

[36] Watt F, Martorana A, Brookes DE, et al. A tissuespecific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics. 2001;73(3):243–254.

[37] Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 1999;59(7):1498–1504.

[38] Xie X, Zhao X, Liu Y, et al. Robust prostate-specific expression and testing of a tissue-specific adenovirus vector. Cancer Gene Ther. 2001;12(5):549–561.

[39] Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology. 2000;141(12):4698–4710.
[40] Lowe SL, Rubinchik S, Honda T, McDonnell TJ, Dong JY, Norris JS. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells. *Gene Ther.* 2001;8(18):1363–1371.

[41] Martiniello-Wilks R, Tsatralis T, Russell P, et al. Transcription-targeted gene therapy for androgen-independent prostate cancer. *Cancer Gene Ther.* 2002;9(5):443–452.

[42] van der Poel HG, McCadden J, Verhaegh GW, et al. A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. *Cancer Gene Ther.* 2001;8(12):927–935.

[43] Miyao Y, Shimizu K, Moriichi S, et al. Selective expression of foreign genes in glioma cells: use of the mouse myelin basic protein gene promoter to direct toxic gene expression. *J Neurosci Res.* 1993;36(4):472–479.

[44] Miyao Y, Shimizu K, Tamura M, et al. Usefulness of a mouse myelin basic protein promoter for gene therapy of malignant glioma: myelin basic protein promoter is strongly active in human malignant glioma cells. *Jpn J Cancer Res.* 1997;88(7):678–686.

[45] Vandier D, Rixe O, Brenner M, Gouyette A, Besnard F. Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene. *Cancer Res.* 1998;58(20):4577–4580.

[46] Vandier D, Rixe O, Besnard F, et al. Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. *Cancer Gene Ther.* 2000;7(8):1120–1126.

[47] McKie EA, Graham DI, Brown SM. Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector—potential glioblastoma targeting. *Gene Ther.* 1998;5(4):440–450.

[48] Morelli AE, Larregina AT, Smith-Arca J, et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. *J Gen Virol.* 1999;80(pt 3):571–583.

[49] Chen J, Bezdek T, Chang J, et al. A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. *Cancer Res.* 1998;58(16):3504–3507.

[50] Shi N, Zhang Y, Zhu C, Boado RJ, Partridge WM. Brain-specific expression of an exogenous gene after i.v. administration. *Proc Natl Acad Sci USA.* 2001;98(22):12754–12759.

[51] Glenn GM, Chatterjee S. Generation of adenoviruses encoding the herpes simplex virus vhs gene: a novel strategy to generate adenoviruses expressing genes toxic to producer cells. *Cancer Gene Ther.* 2001;8(8):566–572.

[52] Shinoura N, Ohashi M, Yoshida Y, et al. Adenovirus-mediated overexpression of Fas induces apoptosis of gliomas. *Cancer Gene Ther.* 2000;7(2):224–232.

[53] Shinoura N, Saito K, Yoshida Y, et al. Adenovirus-mediated transfer of bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas. *Cancer Gene Ther.* 2000;7(5):739–748.

[54] Shinoura N, Koike H, Furtu T, et al. Adenovirus-mediated transfer of caspase-8 augments cell death in gliomas: implication for gene therapy. *Hum Gene Ther.* 2000;11(8):1123–1137.

[55] Martin V, Cortes ML, de Felipe P, Farsetti A, Calcaterra NB, Izquierdo M. Cancer gene therapy by thyroid hormone-mediated expression of toxin genes. *Cancer Res.* 2000;60(12):3218–3224.

[56] Tanaka M, Inase N, Miyake S, Yoshizawa Y. Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma. *Anticancer Res.* 2001;21(1A):291–294.

[57] Ralph GS, Bienemann A, Harding TC, Hopton M, Henley J, Uney JB. Targeting of tetracycline-regulatable transgene expression specifically to neuronal and glial cell populations using adenoviral vectors. *Neuroreport.* 2000;11(9):2051–2055.

[58] Glover CP, Bienemann AS, Heywood DJ, Cosgrave AS, Uney JB. Adenoviral-mediated, high-level, cell-specific transgene expression: a SYN1-WPRE casette mediates increased transgene expression with no loss of neuron specificity. *Mol Ther.* 2002;5(pt 1):509–516.

[59] Narita M, Bahar R, Hatano M, et al. Tissue-specific expression of a suicide gene for selective killing of neuroblastoma cells using a promoter region of the NCX gene. *Cancer Gene Ther.* 2001;8(12):997–1002.

[60] Kuriyama S, Yoshikawa M, Ishizaka S, et al. Selective killing of malignant glioma cells from the GFAP promoter in a HSV RL1 null mutant vector. *Mol Ther.* 2000;5(pt 1):509–516.

[61] Kuriyama S, Sakamoto T, Masui K, et al. Tissue-specific expression of HSV-thy1 gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma. *Int J Cancer.* 1997;71(3):470–475.

[62] Kuriyama S, Sakamoto T, Masui K, et al. Tissue-specific expression of HSV-thy1 gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma. *Int J Cancer.* 1997;71(3):470–475.

[63] Kuriyama S, Sakamoto T, Masui K, et al. Tissue-specific expression of HSV-thy1 gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma. *Int J Cancer.* 1997;71(3):470–475.

[64] Cao G, Kuriyama S, Du P, et al. Construction of retroviral vectors to induce strong hepatoma cell-specific expression of cytokine genes. *J Gastroenterol Hepatol.* 1996;11(11):1053–1061.

[65] Cao G, Kuriyama S, Du P, et al. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer. *Gastroenterology.* 1997;112(2):501–510.
simplex virus thymidine kinase gene. 

[65] Su H, Lu R, Chang JC, Kan YW. Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adenovirus vector increases the growth of human hepatocellular carcinoma in athymic mice. 

[66] Miyatake SI, Tani S, Feigenbaum F, et al. Hepatoma-specific antigen activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. 

[67] Strayer MS, Guttenag SH, Ballard PL. Targeting type II and Clara cells for adenovirus-mediated gene transfer using the surfactant protein B promoter. 

[68] Doronin K, Kuppuswamy M, Toth K, et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. 

[69] Zeiger MA, Takiyama Y, Bishop JO, Ellison AR, Saji M, Levine MA. Adenoviral infection of thyroid cells: a rationale for gene therapy for metastatic thyroid carcinoma. 

[70] Braiden V, Nagayama Y, Iitaka M, Namba H, Niwa M, Yamashita S. Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter. 

[71] Zhang R, Straus FH, DeGroot LJ. Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity. 

[72] Shimura H, Suzuki H, Miyazaki A, et al. Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells. 

[73] Blackwood L, O’Shaughnessy PJ, Reid SW, Argyle DJ, E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy. 

[74] Selvakumaran M, Bao R, Crijns AP, Connolly DC, Weinstein JK, Hamilton TC. Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. 

[75] Bao R, Selvakumaran M, Hamilton TC. Targeted gene therapy of ovarian cancer using an ovarian-specific promoter. 

[76] Yoshimura I, Suzuki S, Tadakuma T, Hayakawa M. Suicide gene therapy on LNCaP human prostate cancer cells. 

[77] Xie X, Zhao X, Liu Y, et al. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. 

[78] Harrington KJ, Linardakis E, Vile RG. Transcriptional control: an essential component of cancer gene therapy strategies? 

[79] Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. 

[80] Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. 

[81] Tahara H, Yasui W, Tahara E, et al. Immunohistochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. 

[82] Komata T, Koga S, Hirohata S, et al. A novel treatment of malignant glioma cells with the transgene expression from the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter. 

[83] Pan CX, Koeneman KS. A novel tumor-specific gene therapy for bladder cancer. 

[84] Abdul-Ghani R, Ohana P, Matouk I, et al. Use of transcriptional regulatory sequences of telomerase (hTERT and hTERT) for selective killing of cancer cells. 

[85] Boyd M, Mairs RJ, Mairs SC, et al. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill. 

[86] Komata T, Koga S, Hirohata S, et al. A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer targeting of prostate-specific association of human telomerase activity with immortal cells and cancer.

[87] Koga S, Hirohata S, Kondo Y, et al. Interferon of constitutively active caspase-6 using the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers.
[91] Plumb JA, Bilsland A, Kakani R, et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. *Oncogene*. 2001;20(53):7797–7803.

[92] Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. *Hum Gene Ther*. 1995;6(7):881–893.

[93] Cao G, Kuriyama S, Gao J, et al. In vivo gene transfer of a suicide gene under the transcriptional control of the carcinoembryonic antigen promoter results in bone marrow transduction but can avoid bone marrow suppression. *Int J Oncol*. 1999;15(1):107–112.

[94] Cao G, Kuriyama S, Gao J, et al. Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter. *Gene Ther*. 1999;6(1):83–90.

[95] Osaki T, Tanio Y, Tachibana I, et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. *Cancer Res*. 1994;54(20):5258–5261.

[96] DiMaio JM, Clary BM, Via DF, Coveney E, Papas TN, Lyerly HK. Directed enzyme prodrug gene therapy for pancreatic cancer in vivo. *Surgery*. 1994;116(2):205–213.

[97] Tanaka T, Kanai F, Okabe S, et al. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. *Cancer Res*. 1996;56(6):1341–1345.

[98] Brand K, Loser P, Arnold W, Bartels T, Strauss M. Tumor cell-specific transgene expression prevents liver toxicity of the aden-HSVtk/GCV approach. *Gene Ther*. 1998;5(10):1363–1371.

[99] Goto H, Osaki T, Kijima T, et al. Target gene therapy utilizing the Cre/loxP system selectively suppresses tumor growth of disseminated carcinoembryonic antigen-producing cancer cells. *Int J Cancer*. 2001;94(3):414–419.

[100] Koch PE, Guo ZS, Kagawa S, Gu J, Roth JA, Fang B. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. *Mol Ther*. 2001;3(3):278–283.

[101] Horimoto M, Sasaki Y, Ugawa S, et al. A novel strategy for cancer therapy by mutated mammalian degenerin gene transfer. *Cancer Gene Ther*. 2000;7(10):1341–1347.

[102] Ueda K, Iwahashi M, Nakamori M, Nakamura M, Yamaue H, Tanimura H. Enhanced selective gene expression by adenovirus vector using Cre/loxP regulation system for human carcinoembryonic antigen-producing carcinoma. *Oncology*. 2000;59(3):255–265.

[103] Ueda K, Iwahashi M, Nakamori M, et al. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model. *Cancer Res*. 2001;61(16):6158–6162.

[104] Kijima T, Osaki T, Nishino K, et al. Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. *Cancer Res*. 1999;59(19):4906–4911.

[105] Qiao J, Doubrovin M, Sauter BV, et al. Tumor-specific transcriptional targeting of suicide gene therapy. *Gene Ther*. 2002;9(3):168–175.

[106] Ishikawa H, Nakata K, Mawatari F, et al. Utilization of variant-type of human alpha-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma. *Gene Ther*. 1999;6(4):465–470.

[107] Ishikawa H, Nakata K, Mawatari F, et al. Retrovirus-mediated gene therapy for hepatocellular carcinoma with reversely oriented therapeutic gene expression regulated by alpha-fetoprotein enhancer/promoter. *Biochem Biophys Res Commun*. 2001;287(4):1034–1040.

[108] Kanai F, Lan KH, Shiratori Y, et al. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. *Cancer Res*. 1997;57(3):461–465.

[109] Bui LA, Butterfield LH, Kim JY, et al. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. *Hum Gene Ther*. 1997;8(18):2173–2182.

[110] Cao G, Kuriyama S, Tsujinoue H, Chen Q, Mitoro A, Qi Z. A novel approach for inducing enhanced and selective transgene expression in hepatocellular-carcinoma cells. *Int J Cancer*. 2000;87(2):247–252.

[111] Murayama Y, Tadakuma T, Kunitomi M, et al. Cell-specific expression of the diphtheria toxin A-chain coding sequence under the control of the upstream region of the human alpha-fetoprotein gene. *J Surg Oncol*. 1999;70(3):145–149.

[112] Ohashi M, Kanai F, Tateishi K, et al. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. *Biochem Biophys Res Commun*. 2001;282(2):529–535.

[113] Sato Y, Tanaka K, Lee G, et al. Enhanced and specific gene expression via tissue-specific production of Cre recombinase using adenovirus vector. *Biochem Biophys Res Commun*. 1998;244(2):455–462.

[114] Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR. Gene therapy for cancer using tumour-specific prodrug activation. *Gene Ther*. 1994;1(3):170–175.

[115] Sikora K, Harris J, Hurst H, Lemoine N. Therapeutic strategies using c-erbB-2 promoter-controlled
drug activation. *Ann N Y Acad Sci.* 1994;716:115–124; discussion 124–125, 140–143.

[116] Stackhouse MA, Buchsbaum DJ, Kancharla SR, et al. Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adeno-viral vectors. *Cancer Gene Ther.* 1999;6(3):209–219.

[117] Maeda T, O-Wang J, Matsubara H, et al. A minimum c-erbB-2 promoter-mediated expression of herpes simplex virus thymidine kinase gene confers selective cytotoxicity of human breast cancer cells to ganciclovir. *Cancer Gene Ther.* 2001;8(11):890–896.

[118] Manome Y, Abe M, Hagen MF, Fine HA, Kufe DW. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. *Cancer Res.* 1994;54(20):5408–5413.

[119] Chen L, Pulsipher M, Chen D, et al. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. *J Clin Invest.* 1995;96(6):2775–2782.

[120] Chen L, Pulsipher M, Chen D, et al. Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. *J Clin Invest.* 1996;98(11):2539–2548.

[121] Tai YT, Strobel T, Kufe D, Cannistra SA. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. *Cancer Res.* 1999;59(9):2121–2126.

[122] Koeneman KS, Kao C, Ko SC, et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. *World J Urol.* 2000;18(2):102–110.

[123] Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to target prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. *Cancer Res.* 2001;61(16):6012–6019.

[124] Benjamin R, Helman L, Meyers P, Reaman G. A phase I/II dose escalation and activity study of intravenous injections of OCaP1 with subjects with refractory osteosarcoma metastatic to lung. *Hum Gene Ther.* 2001;12(12):1591–1593.

[125] Shirakawa T, Ko SC, Gardner TA, et al. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. *Cancer Gene Ther.* 1998;5(5):274–280.

[126] Yeung F, Law WK, Yeh CH, et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. *J Biol Chem.* 2002;277(4):2468–2476.

[127] Chung I, Schwartz PE, Crystal RG, Pizzorno G, Leavitt J, Deisseroth AB. Use of L-plastin promoter to develop an adeno-viral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells. *Cancer Gene Ther.* 1999;6(2):99–106.

[128] Peng XY, Won JH, Rutherford T, et al. The use of the L-plastin promoter for adeno-viral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. *Cancer Res.* 2001;61(11):4405–4413.

[129] Miyauchi M, Shimada H, Kadomatsu K, et al. Frequent expression of midkine gene in esophageal cancer suggests a potential usage of its promoter for suicide gene therapy. *Jpn J Cancer Res.* 1999;90(4):469–475.

[130] Adachi Y, Reynolds PN, Yamamoto M, et al. Midkine promoter-based adeno-viral vector gene delivery for pediatric solid tumors. *Cancer Res.* 2000;60(16):4305–4310.

[131] Adachi Y, Matsubara S, Muramatsu T, Curiel DT, Reynolds PN. Midkine promoter-based adeno-viral suicide gene therapy to midkine-positive pediatric tumor. *J Pediatr Surg.* 2002;37(4):588–592.

[132] Casado E, Gomez-Navarro J, Yamamoto M, et al. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. *Clin Cancer Res.* 2001;7(8):2496–2504.

[133] Wesseling JG, Yamamoto M, Adachi Y, et al. Midkine and cyclooxygenase-2 promoters are promising for adeno-viral vector gene delivery of pancreatic carcinoma. *Cancer Gene Ther.* 2001;8(12):990–996.

[134] Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS, Vasserot AP. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. *Gene Ther.* 2001;8(7):568–578.

[135] Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. *Gene Ther.* 2002;9(1):30–37.

[136] Komata T, Kanzawa T, Kondo Y, Kondo S. Telomerase as a therapeutic target for malignant gliomas. *Oncogene.* 2002;21(4):656–663.

[137] Kyo S, Takakura M, Inoue M. Telomerase activity in human colorectal carcinoma using human CEA antigen-producing gastric carcinoma. *Cancer Res.* 2001;61(11):4405–4413.

[138] Lan KH, Kanai F, Shiratori Y, et al. Telomerase activity in cancer as a diagnostic and therapeutic target. *Histol Histopathol.* 2000;15(3):813–824.

[139] Lan KH, Kanai F, Shiratori Y, et al. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. *Cancer Res.* 1997;57(19):4279–4284.

[140] Cao GW, Qi ZT, Pan X, et al. Gene therapy for human colorectal carcinoma using human CEA promoter contro led bacterial ADP-ribosylating toxin genes human CEA: PEA & DTA gene transfer. *World J Gastroenterol.* 1998;4(5):388–391.
[140] Nishino K, Osaki T, Kumagai T, et al. Adenovirus-mediated gene therapy specific for small cell lung cancer cells using a Myc-Max binding motif. *Int J Cancer*. 2001;91(6):851–856.

[141] Humphreys MJ, Ghanem P, Greenhalf W, et al. Hepatic intra-arterial delivery of a retroviral vector expressing the cysteine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases. *Gene Ther*. 2001;8(16):1241–1247.

[142] Tanaka S, Iwai M, Harada Y, et al. Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter. *Cancer Gene Ther*. 2000;7(9):1241–1250.

[143] Nyati MK, Seekumara A, Li S, et al. High and selective expression of yeast cysteine deaminase under a carcinoembryonic antigen promoter-enhancer. *Cancer Res*. 2002;62(8):2337–2342.

[144] Tanaka T, Kanai F, Lan KH, et al. Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo. *Biochem Biophys Res Commun*. 1997;231(3):775–779.

[145] Ido A, Uto H, Moriiuchi A, et al. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. *Cancer Res*. 2001;61(7):3016–3021.

[146] Maxwell IH, Spitzer AL, Long CJ, Maxwell F. Autonomous parvovirus transduction of a gene under control of tissue-specific or inducible promoters. *Gene Ther*. 1996;3(1):28–36.

[147] Wills KN, Huang WM, Harris MP, Machemer T, Maneval DC, Gregory RJ. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. *Cancer Gene Ther*. 1995;2(3):191–197.

[148] Kaneko S, Hallenbeck P, Kotani T, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. *Cancer Res*. 1995;55(22):5283–5287.

[149] Ido A, Nakata K, Kato Y, et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. *Cancer Res*. 1995;55(14):3105–3109.

[150] Hernandez-Alcoceba R, Pihalja M, Nunez G, Clarke MF. Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. *Cancer Gene Ther*. 2001;8(4):298–307.

[151] Takakuwa K, Fujita K, Kikuchi A, et al. Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA-liposome complexes: growth inhibition of tumors and lack of localization in normal tissues. *Jpn J Cancer Res*. 1997;88(2):166–175.

[152] Zheng S, Wang S, Ma L, Sun K. HER2 promoter controlled specific expression of the reporter gene in ovarian cancer cell line [in Chinese]. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. 2000;17(5):313–315.

[153] Patterson A, Harris AL. Molecular chemotherapy for breast cancer. *Drugs Aging*. 1999;14(2):75–90.

[154] Zaretsky JZ, Sarid R, Aylon Y, Mittelman LA, Wreschner DH, Keydar I. Analysis of the promoter of the MUC1 gene overexpressed in breast cancer. *FEBS Lett*. 1999;461(3):189–195.

[155] Ko SC, Cheon J, Kao C, et al. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. *Cancer Res*. 1996;56(20):4614–4619.

[156] Cheon J, Ko SC, Gardner TA, et al. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. *Cancer Gene Ther*. 1997;4(6):359–365.

[157] Robertson MW 3rd, Wang M, Siegal GP, et al. Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells. *Cancer Gene Ther*. 1998;5(5):331–336.

[158] Garver RJ Jr, Goldsmith KT, Rodu B, Hu PC, Sorscher EJ, Curiel DT. Strategy for achieving selective killing of carcinomas. *Gene Ther*. 1994;1(1):46–50.

[159] Anderson LM, Krotz S, Weitzman SA, Thimmappaya B. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach. *Cancer Gene Ther*. 2000;7(6):845–852.

[160] Kumagai T, Tanio Y, Osaki T, et al. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements. *Cancer Res*. 1996;56(2):354–358.

[161] Sugaya S, Fujita K, Kikuchi A, et al. Inhibition of tumor growth by direct intratumoral gene transfer of herpes simplex virus thymidine kinase gene with DNA-liposome complexes. *Hum Gene Ther*. 1996;7(2):223–230.

[162] Lung RW, Lee KA. The cellular oncogene EWS/activating transcription factor 1 is unable to activate adenovirus-borne promoters: implications for cytotoxic prodrg therapy of malignant melanoma of soft parts. *Cancer Gene Ther*. 2000;7(3):396–406.

[163] Yamamoto M, Alemayehu R, Adachi Y, Grizzle WE, Curiel DT. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. *Mol Ther*. 2001;3(3):385–394.
[164] Iyengar RV, Pawlik CA, Krull EJ, et al. Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression. Cancer Res. 2001;61(7):3045–3052.

[165] McLaughlin PM, Harmsen MC, Dokter WH, et al. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res. 2001;61(10):4105–4111.

[166] Nawrath M, Pavlovic J, Moelling K. Inhibition of human hematopoietic tumor formation by targeting a repressor Myb-KRAB to DNA. Cancer Gene Ther. 2000;7(6):963–972.

[167] Inase N, Horita K, Tanaka M, Miyake S, Ichioka M, Yoshizawa Y. Use of gastrin-releasing peptide promoter for specific expression of thyminase kinase gene in small-cell lung carcinoma cells. Int J Cancer. 2000;85(5):716–719.

[168] Morimoto E, Inase N, Miyake S, Yoshizawa Y. Adenovirus-mediated suicide gene transfer to small cell lung carcinoma using a tumor-specific promoter. Anticancer Res. 2001;21(1A):329–331.

[169] Vandier D, Calvez V, Massade L, et al. Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy. J Natl Cancer Inst. 2000;92(8):642–647.

[170] Yamamura H, Hashio M, Noguchi M, et al. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res. 2001;61(10):3969–3977.

[171] Ohana P, Bibi O, Matouk I, et al. Use of H19 regulatory sequences for targeted gene therapy in cancer. Int J Cancer. 2002;98(5):645–650.

[172] Chen RH, McCormick F. Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells. Cancer Res. 2001;61(11):4445–4449.

[173] Lipinski KS, Djeha AH, Krausz E, et al. Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53. Gene Ther. 2001;8(4):274–281.

[174] Inase N, Miyake S, Yoshizawa Y. Calretinin promoter for suicide gene expression in malignant mesothelioma. Anticancer Res. 2001;21(2A):1111–1114.

[175] Messina M, Yu DM, Learoyd DL, Both GW, Molloy PL, Robinson BG. High level, tissue-specific expression of a modified calcitonin/calcitonin gene-related peptide promoter in a human medullary thyroid carcinoma cell line. Mol Cell Endocrinol. 2000;164(1-2):219–224.

[176] Minemura K, Takeda T, Minemura K, et al. Cell-specific induction of sensitivity to ganciclovir in medullary thyroid carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Endocrinology. 2000;141(5):1814–1822.

[177] Yamazaki M, Zhang R, Straus FH, et al. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Ther. 2002;9(1):64–74.

[178] Nettelbeck DM, Zwicker J, Lucibello FC, et al. Cell cycle regulated promoters for the targeting of tumor endothelium. Adv Exp Med Biol. 1998;451:437–440.

[179] Nettelbeck DM, Jerome V, Muller R. A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control. Gene Ther. 1999;6(7):1276–1281.

[180] Velasco B, Ramirez JR, Relloso M, et al. Vascular gene transfer driven by endoglin and ICAM-2 endothelial-specific promoters. Gene Ther. 2001;8(12):897–904.

[181] Werner H, Shalita-Chesner M, Abramovich S, Idelman G, Shaharabani-Gargir L, Glaser T. Regulation of the insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: implications in human cancer. Mol Genet Metab. 2000;71(1-2):315–320.

[182] Parr MJ, Manome Y, Tanaka T, et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med. 1997;3(10):1145–1149.

[183] Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93(4):266–276.

[184] Jaggar RT, Chan HY, Harris AL, Bicknell R. Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery. Hum Gene Ther. 1997;8(18):2239–2247.

[185] Szary J, Kalita K, Przybyszewska M, et al. KDR promoter can transcriptionally target cytokine-deaminase suicide gene to cancer cells of nonendothelial origin. Anticancer Res. 2001;21(5):3471–3475.

[186] Modlich U, Pugh CW, Bicknell R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther. 2000;7(10):896–902.

[187] Heidenreich R, Kappel A, Breier G. Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor receptor-2 (Flk-1) promoter/enhancer sequences. Cancer Res. 2000;60(21):6142–6147.

[188] Bauerschmitz GJ, Nettelbeck DM, Kanerva A, et al. The flt-1 promoter for transcriptional targeting of teratocarcinoma. Cancer Res. 2002;62(5):1271–1274.

[189] Walton T, Wang JI, Ribas A, Barsky SH, Economou J, Nguyen M. Endothelium-specific expression of
an E-selectin promoter recombinant adenoviral vector. Anticancer Res. 1998;18(3A):1357–1360.

[190] Ozaki K, Yoshida T, Ide H, et al. Use of von Willebrand factor promoter to transduce suicidal gene to human endothelial cells, HUVEC. Hum Gene Ther. 1996;7(13):1483–1490.

[191] Jager U, Zhao Y, Porter CD. Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human propro-endothelin-1 promoter sequences. J Virol. 1999;73(12):9702–9709.

[192] Mavria G, Jager U, Porter CD. Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo. Gene Ther. 2000;7(5):368–376.

[193] Varda-Bloom N, Shaish A, Gonen A, et al. Tissue-specific gene therapy directed to tumor angiogene- sis. Gene Ther. 2001;8(11):819–827.

[194] Shibata T, Akiyama N, Noda M, Sasai K, Hiraoka M. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int J Radiat Oncol Biol Phys. 1998;42(4):913–916.

[195] Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 2000;7(6):493–498.

[196] Shibata T, Giaccia AJ, Brown JM. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia. 2002;4(1):40–48.

[197] Koshikawa N, Takenaka K, Tagawa M, Sakiyama S. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res. 2000;60(11):2936–2941.

[198] Ruan H, Su H, Hu L, Lamborn KR, Kan YW, Deen DF. A hypoxia-regulated adenovirus-associated virus vector for cancer-specific gene therapy. Neoplasia. 2001;3(3):255–263.

[199] Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med. 1997;3(5):515–520.

[200] Little E, Ramakrishnan M, Roy B, Gazit G, Lee AS. The glucose-regulated proteins (GRP78 and GRP94): functions, gene regulation, and applications. Crit Rev Eukaryot Gene Expr. 1994;4(1):1–18.

[201] Gazit G, Kane SE, Nichols P, Lee AS. Use of the stress-inducible grp78/BiP promoter in targeting high level gene expression in fibrosarcoma in vivo. Cancer Res. 1995;55(8):1660–1663.

[202] Gazit G, Hung G, Chen X, Anderson WF, Lee AS. Use of the glucose starvation-inducible glucose-regulated protein 78 promoter in suicide gene therapy of murine fibrosarcoma. Cancer Res. 1999;59(13):3100–3106.

[203] Chen X, Zhang D, Dennert G, Hung G, Lee AS. Eradication of murine mammary adenocarcinoma through HSVtk expression directed by the glucose-starvation inducible grp78 promoter. Breast Cancer Res Treat. 2000;59(1):81–90.

[204] Luna MC, Chen X, Wong S, et al. Enhanced photodynamic therapy efficacy with inducible suicide gene therapy controlled by the grp promoter. Cancer Res. 2002;62(5):1458–1461.

[205] Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci. 2001;26(8):504–510.

[206] Katabi MM, Chan HL, Karp SE, Batist G. Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. Hum Gene Ther. 1999;10(2):155–164.

[207] Harats D, Kurihara H, Belloni P, et al. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. J Clin Invest. 1995;95(3):1335–1344.

[208] Nettelbeck DM, Jerome V, Muller R. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters. Gene Ther. 1998;5(12):1656–1664.

[209] Marples B, Greco O, Joiner MC, Scott SD. Molecular approaches to chemo-radiotherapy. Eur J Cancer. 2002;38(2):231–239.

[210] Kawashita Y, Ohtsuru A, Kaneda Y, et al. Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation. Hum Gene Ther. 1999;10(9):1509–1519.

[211] Manome Y, Kunieda T, Wen PY, Koga T, Kufe DW, Ohno T. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iodo-deoxyuridine. Hum Gene Ther. 1998;9(10):1409–1417.

[212] Seung LP, Mauceri HJ, Beckett MA, Hallahan DE, Hellman S, Weichselbaum RR. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res. 1995;55(23):5561–5565.

[213] Weichselbaum RR, Hallahan DE, Beckett MA, et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 1994;54(16):4266–4269.

[214] Mauceri HJ, Hanna NN, Wayne JD, Hallahan DE, Hellman S, Weichselbaum RR. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 1996;56(19):4311–4314.

[215] Mauceri HJ, Seung LP, Grdina WL, Swedberg KA, Weichselbaum RR. Increased injection number enhances adenoviral genetic radiotherapy. Radiat Oncol Invest. 1997;5(5):220–226.

[216] Hallahan DE, Mauceri HJ, Seung LP, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med. 1995;1(8):786–791.
[217] Hallahan DE, Qu S, Geng L, et al. Radiation-mediated control of drug delivery. *Am J Clin Oncol.* 2001;24(5):473–480.

[218] Weichselbaum RR, Kufe DW, Advani SJ, Roisman B. Molecular targeting of gene therapy and radiotherapy. *Acta Oncol.* 2001;40(6):735–738.

[219] Scott SD, Marples B, Hendry JH, et al. A radiation-controlled molecular switch for use in gene therapy of cancer. *Gynecol Oncol.* 2000;73(1):1121-1125.

[220] Hanna NN, Hallahan DE, Wayne JD, Weichselbaum RR. Modification of the radiation response by the administration of exogenous genes. *Semin Radiat Oncol.* 1996;6(4):321-328.

[221] Kaminski JM, Kaminski RJ, Dicker AP, Urbain JL. Defining a future role for radiogenic therapy. *Cancer Treat Rev.* 2001;27(5):289–294.

[222] Worthington J, Robson T, Murray M, O’Rourke M, Keilty G, Hirst DG. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. *Gynecol Oncol.* 2000;73(1):1126–1131.

[223] Worthington J, Robson T, O’Keeffe M, Hirst DG. Tumour cell radiosensitivity using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy. *Gynecol Oncol.* 2002;9(4):263–269.

[224] Nuys S, Van Mellaert L, Theys J, et al. Radiosensitive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation. *Gynecol Oncol.* 2001;8(15):1197–1201.

[225] Nuys S, Van Mellaert L, Theys J, Landuyt W, Lambin P, Anne J. The use of radiation-induced bacterial promoters in anaerobic conditions: a means to control gene expression in clostridium-mediated therapy for cancer. *Radiat Res.* 2001;155(5):716–723.

[226] Ueda T, Akiyama N, Sai H, et al. c-IAP2 is induced by ionizing radiation through NF-kappaB binding sites. *FEBS Lett.* 2001;491(1-2):40–44.

[227] Madic DP, van Gelderen P, Despres D, et al. On the feasibility of MRI-guided focused ultrasound for local induction of gene expression. *J Magn Reson Imaging.* 1998;8(1):101–104.

[228] Braiden V, Ohtsuru A, Kawashita Y, et al. Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter. *Hum Gene Ther.* 2000;11(18):2453–2463.

[229] Lee YJ, Galoforo SS, Battle P, Lee H, Corry PM, Jessup JM. Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy. *Cancer Gene Ther.* 2001;8(6):397–404.

[230] Lohr F, Hu K, Huang Q, et al. Enhancement of radiotherapy by hyperthermic-regulated gene therapy. *Int J Radiat Oncol Biol Phys.* 2000;48(5):1513–1518.

[231] Lohr F, Huang Q, Hu K, Dewhirst MW, Li CY. Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors. *Clin Cancer Res.* 2001;7(11):3625–3628.

[232] Brade AM, Ngo D, Szmitko P, Li PX, Liu FF, Klamut HJ. Heat-directed gene targeting of adenoviral vectors to tumor cells. *Cancer Gene Ther.* 2000;7(12):1566–1574.

[233] Huang Q, Hu JK, Lohr F, et al. Heat-induced gene expression as a novel targeted cancer gene therapy strategy. *Cancer Res.* 2000;60(13):3435–3439.

[234] Vekris A, Mauранge C, Moonen C, et al. Control of transgene expression using local hyperthermia in combination with a heat-sensitive promoter. *J Gene Med.* 2000;2(2):89–96.

[235] Ito A, Shinkai M, Honda H, Kobayashi T. Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy. *Cancer Gene Ther.* 2001;8(9):649–654.

[236] Walther W, Stein U, Fichtner I, Alexander M, Shoemaker RH, Schlag PM. Mdr1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors. *Cancer Gene Ther.* 2000;7(6):893–900.

[237] Walther W, Stein U, Schlag PM. Use of the human MDR1 promoter for heat-inducible expression of therapeutic genes. *Int J Cancer.* 2002;98(2):291–296.

[238] Walther W, Stein U, Fichtner I, et al. In vivo evaluation of a drug-inducible vector system for the combined gene- and chemotherapy of cancer. *Adv Exp Med Biol.* 1998;451:139–144.

[239] Patil R, Chavez JB, Yee D. Inducible expression of herpes simplex virus thymidine kinase increases sensitivity to ganciclovir but does not enhance bystander effect in breast cancer cells. *Breast Cancer Res Treat.* 2000;62(2):109–115.

[240] Pitzer C, Schindowski K, Pomer S, Wirth T, Zoller M. In vivo manipulation of interleukin-2 expression by a retroviral tetracycline (tet)-regulated system. *Cancer Gene Ther.* 1999;6(2):139–146.

[241] Yu JS, Sena-Esteves M, Paulus W, Breakfield XO, Reeves SA. Retroviral delivery and tetracycline-dependent expression of IL-1beta-converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells. *Cancer Res.* 1996;56(23):5423–5427.

[242] Rubinchik S, Wang D, Yu H, et al. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. *Mol Ther.* 2001;4(5):416–426.

[243] Iida A, Chen ST, Friedmann T, Yee JK. Inducible gene expression by retrovirus-mediated transfer of a modified tetracycline-regulated system. *J Virol.* 1996;70(9):6054–6059.
Baasner S, von Melchner H, Kleiner T, Hilgard P, Beckers T. Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase. Oncogene. 1996;13(5):901–911.

Paulus W, Baur I, Oberer DM, Breakefield XO, Reeves SA. Regulated expression of the diphertheria toxin A gene in human glioma cells using prokaryotic transcriptional control elements. J Neurosurg. 1997;87(1):89–95.

Yao F, Svensjo T, Winkler T, Lu M, Eriksson C, Eriksson E. Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum Gene Ther. 1998;9(13):1939–1950.

Giavazzi R, Giuliani R, Coltrini D, et al. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Res. 2001;61(1):309–317.

Chong H, Ruchatz A, Clackson T, Rivera VM, Vile RG. A system for small-molecule control of conditionally replication-competent adenoaviral vectors. Mol Ther. 2002;5(2):195–203.

Hernandez-Alcoceba R, Pihalja M, Wicha MS, Clarke MF. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hum Gene Ther. 2000;11(14):2009–2024.

Tannour-Louet M, Porteu A, Vaulont S, Kahn A, Vasseur-Cognet M. A tamoxifen-inducible chimeric Cre recombinase specifically effective in the fetal and adult mouse liver. Hepatology. 2002;35(5):1072–1081.

Datta R, Taneja N, Sukhatme VP, Qureshi SA, Weichselbaum R, Kufe DW. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci USA. 1993;90(6):2419–2422.

Joki T, Nakamura M, Ohno T. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Hum Gene Ther. 1995;6(12):1507–1513.

Marples B, Scott SD, Hendry JH, Embleton MJ, Lashford LS, Margison GP. Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther. 2000;7(6):511–517.

Yook JI, Kim J. Expression of p21WAF1/CIP1 is unrelated to p53 tumour suppressor gene status in oral squamous cell carcinomas. Oral Oncol. 1998;34(3):198–203.

Codegoni AM, Nicoletti MI, Buraggi G, et al. Molecular characterisation of a panel of human ovarian carcinoma xenografts. Eur J Cancer. 1998;34(9):1432–1438.

Clasen S, Schulz WA, Gerharz CD, Grimm MO, Christoph F, Schmitz-Drager BJ. Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Br J Cancer. 1998;77(4):515–521.

Sourvinos G, Spandidos DA. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem Biophys Res Commun. 1998;245(1):75–80.

Waslyhlc K, Salvi R, Argentini M, et al. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene. 1999;18(11):1921–1934.

Schwerer MJ, Sailer A, Kraft K, Baczkó K, Maier H. Patterns of p21(waf1/cip1) expression in non-papillomatous nasal mucosa, endophytic sinonasal papillomas, and associated carcinomas. J Clin Pathol. 2001;54(11):871–876.

Biankin AV, Kench JG, Morey AL, et al. Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res. 2001;61(24):8830–8837.

O’Hanlon DM, Kiely M, MacConnara M, et al. An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma. Eur J Surg Oncol. 2002;28(2):103–107.

Vidal MJ, Loganzo F Jr, de Oliveira AR, Hayward NK, Albino AP. Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res. 1995;5(4):243–250.

Karjalainen JM, Eskelinen MJ, Kellokoski JK, Reinkainen M, Ahlava EM, Kosma VM. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. Br J Cancer. 1999;79(5–6):895–902.

Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des. 1999;14(6):473–486.

McCarthy HO, Yakkundi A, McElrane V, et al. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther. 2003;10(1):40–48.

Nuysts S, Van Mellaert L, Theys J, Landuyt W, Lambin P, Anne J. Clostridium spores for tumor-specific drug delivery. Anticancer Drugs. 2002;13(2):115–125.

Nielsen OS, Horsman M, Overgaard J. A future for hyperthermia in cancer treatment? Eur J Cancer. 2001;37(13):1587–1589.

Arai Y, Kubo T, Kobayashi K, et al. Control of delivered gene expression in chondrocytes using heat shock protein 70B promoter. J Rheumatol. 1999;26(8):1769–1774.
[269] Lin H, Blank M, Rossol-Haseroth K, Goodman R. Regulating genes with electromagnetic response elements. *J Cell Biochem.* 2001;81(1):143–148.

[270] Stein U, Walther W, Shoemaker RH. Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type-specific and dose-dependent. *J Cancer Res Clin Oncol.* 1996;122(5):275–282.

[271] Walther W, Wendt J, Stein U. Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy. *Gene Ther.* 1997;4(6):544–552.

[272] Zhang L, Adams JY, Billick E, et al. Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. *Mol Ther.* 2002;5(3):223–232.

[273] Lee EJ, Jameson JL. Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy. *Hum Gene Ther.* 2002;13(4):533–542.

[274] Yoshimura I, Suzuki S, Hayakawa M. Application of Cre-loxP system to the urinary tract and cancer gene therapy. *Mol Urol.* 2001;5(2):81–84.

[275] Iyer M, Wu L, Carey M, Wang Y, Smallwood A, Gambhir SS. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. *Proc Natl Acad Sci USA.* 2001;98(25):14595–14600.

[276] Jounaidi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. *Cancer Res.* 2000;60(14):3761–3769.

[277] Putzer BM, Stiewe T, Crespo F, Esche H. Improved safety through tamoxifen-regulated induction of cytotoxic genes delivered by Ad vectors for cancer gene therapy. *Gene Ther.* 2000;7(15):1317–1325.

* Corresponding author.

E-mail: t.robson@ulster.ac.uk

Fax: +44 2890366808; Tel: +44 2890366116